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INTRODUCTION 
A fundamental problem in neuroscience is explaining the neurobiological 
mechanisms involved in learning.  One way this issue has been studied is by 
investigating the effects of drugs on neurobiological systems that are thought to 
be involved in memory and learning. The present thesis addresses the issue of 
the effects on spatial learning of drugs from three classes (N-methyl-D-aspartate 
receptor antagonists, gamma-aminobutyric acid agonists, and muscarinic 
cholinergic antagonists) and examines the way that these drugs interact when 
compounds from each class are administered in combination. 
Glutamate and acetylcholine (excitatory neurotransmitters) and GABA 
(inhibitory neurotransmitter) are three neurotransmitter systems that have been 
linked to learning and memory.  These neurotransmitters differ in their general 
effects on postsynaptic membranes.  Excitatory neurotransmitters, like glutamate 
and acetylcholine, depolarize the postsynaptic membrane.  Conversely, GABA 
hyperpolarizes the postsynaptic membrane, producing an inhibitory postsynaptic 
potential.  The two simple amino acids, glutamate and GABA, are the most 
abundant neurotransmitters in the CNS (Feldman, Meyer and Quenzer, 1997). 
Neuropharmacology of Glutamate 
Four types of glutamate receptors have been discovered.  Three are 
ionotropic (the NMDA receptor, the AMPA receptor, and the kainate receptor) 
and the fourth receptor is metabotropic.   Ionotropic receptors are receptors that 
contain a binding site for a neurotransmitter (the location on a receptor protein to 
which a ligand binds) and an ion channel, which opens or closes when a 
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molecule of the transmitter attaches to the binding site.  Metabotropic receptors 
activate an enzyme that begins a series of chemical events that affect ion 
channels elsewhere in the membrane of the postsynaptic cell when a molecule of 
neurotransmitter attaches to the binding site.  Although the AMPA (alpha-amino-
3-hydroxy-5-methylisoxazole propionate) receptor appears to be the most widely 
distributed glutamate receptor, the N-methyl-D-aspartate receptor has attracted 
much attention because of several unique properties of this receptor.  It has six 
different binding sites (one of which is for glutamate), and when it is open, the ion 
channel controlled by the NMDAR allows sodium and calcium ions to enter the 
postsynaptic cell, which causes a depolarization (Feldman et al., 1997).  
According to numerous reports, excessive release of glutamate and prolonged 
stimulation of NMDA receptors are produced by ischemia and seizure.  NMDAR 
antagonists have been shown to decrease neuronal damage and to have 
anticonvulsive properties in the experimental models of such neuropathologies 
(Ylinen, Pitkanen, Sirvio, Hartikainen, Sivenius, Koivisto, and Riekkinen, 1995).  
There are two principal concepts in neuropharmacology of 
neurotransmitters.  Drugs that affect synaptic transmission are classified into two 
general categories.  Antagonists are compounds that oppose or inhibit an effect 
of particular neurotransmitter on the postsynaptic membrane.  Agonists are the 
drugs that facilitate the effects of transmitter (Feldman et al., 1997).  Obviously, 
N-methyl-D-aspartate (NMDA) serves as direct agonist of NMDA receptors.  A 
hallucinogenic synthetic drug phencyclidine (PCP) binds to one of the six binding 
sites.  PCP blocks the calcium channel and, thus, serves as an indirect 
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antagonist (indirect means that drug does not interfere with the binding site for 
the principal ligand when it attaches to its receptor).  There are several other 
drugs that affect glutamatergic synapses: competitive NMDAR antagonists (AP5, 
CPP, CGS 19755) bind to NMDA receptors, and the non-competitive antagonist 
MK-801 (dizocilpine) binds to PCP receptor-site.  Competitive binding of agonists 
or antagonists acts directly on the neurotransmitter binding site whereas non-
competitive binding of indirect agonists or antagonists acts on alternative binding 
site and modifies the effects of the transmitter on the ion channel controlled by 
the neurotransmitter (Feldman et al., 1997).  Because non-competitive agents 
MK-801 and PCP are effective after systemic administration, they have been 
studied intensively by behavioral pharmacologists who are interested in exploring 
the role of NMDA receptors in memory (Wozniak, Olney, Kettinger III, Price, and 
Miller, 1990).  
Neuropharmacology of GABA 
Two GABA (gamma-aminobutyric acid) receptors have been identified: 
GABAA and GABAB.  The GABAA receptor is ionotropic and controls a chloride 
channel; the GABAB receptor is metabotropic and controls a potassium channel 
(Feldman et al., 1997).  The GABA system has a wide-spread distribution 
throughout the brain and spinal cord. 
Like the NMDA receptor, the GABAA receptor is complex and consists of 
the multiple binding sites.  GABA binds to the main site and this binding can be 
antagonized by bicuculline.  A second site binds with benzodiazepines.  
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Barbiturates bind to yet a third binding site.  All of the mentioned compounds 
serve as modulators of the GABAA receptor-complex (Feldman et al., 1997).   
Neuropharmacology of Acetylcholine 
Like glutamate and GABA, acetylcholine is a neurotransmitter that is 
widely distributed throughout the brain.  Released ACh generally produces 
excitatory effects.  The acetylcholine neurons located in the basal forebrain and 
medial septum are involved in facilitating learning and formation of memories 
(Feldman et al., 1997).  There are two different types of ACh receptors - 
ionotropic and metabotropic with different drugs activating each type of 
receptors.  The ionotropic receptors are stimulated by nicotine and metabotropic 
are stimulated by muscarine, a substance naturally found in poison mushrooms.  
Thus, the two types of receptors are referred to as nicotinic and muscarinic 
receptors.  Although both types are present in the central nervous system, 
muscarinic receptors predominate in CNS.  Nicotinic receptors are contained in 
muscle fibers.  Because metabotropic receptors control ion channels by the chain 
of secondary messengers, action of muscarinic receptors are slower and more 
prolonged than those of nicotinic ones (Feldman et al., 1997).   
Drugs known as antimuscarinic or muscarinic cholinergic blocking agents 
antagonize the muscarinic actions of ACh and produce their effects at nicotinic 
receptor sites.  The best-known member of this class of drugs is atropine, a 
naturally occurring alkaloid from the plant Atropa belladonna.  Another well-
known antimuscarinic drug is an alkaloid scopolamine, which is naturally found in 
the shrub Hyoscyamus niger and Scopolia carniolica.   
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Drugs that block central acetylcholine (ACh) muscarinic receptors have 
long been known to impair higher cognitive functions and induce amnestic states 
(Coyle, Price & DeLong, 1983).  Behavioral effects of these antimuscarinic 
compounds will be of particular interest with respect to the experiments 
described in this thesis.  
NMDAR Antagonist Effects on Spatial Learning 
 Rats are skillful at learning locations.  Morris (1981) demonstrated that 
rats can rapidly learn to locate an object that they can never see, smell or hear 
provided it remains in a fixed spatial location relative to distal room cues.  In 
Morris's classic study (1981) rats were placed in the circular pool of water and 
had to swim to an escape platform, which was submerged below the surface of 
murky water.  Morris referred to this experimental condition as the place 
condition.  In another experimental condition the top of the platform was several 
centimeters above the surface and rats could see it, which Morris termed as the 
cue condition.  In the experiment the following conditions were contrasted: 1) 
cue+place - the escape platform was always visible and always in the same 
location; 2) place - the platform was submerged but always in the same location; 
3) cue only - the platform was always visible but in the different locations on 
different trials; 4) place random - the platform was submerged and in different 
locations.  The rats performed well in all conditions but the fourth one, in which 
rats took much longer to find the escape platform.  During a probe test in which 
the escape platform was removed from the pool, rats trained in the place and cue 
only conditions preferentially searched in the region of the pool where the 
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platform was located during training.  The fact that rats rapidly learned to swim 
directly to the hidden platform in the place condition and searched for the missing 
platform in the place where it was located during training both indicated that rats 
can use extrapool stimuli to navigate to the escape platform (Morris, 1981). 
To investigate whether NMDA receptors were necessary for place 
learning, Morris, Anderson, Lynch and Baudry (1986) carried out an experiment 
in the water maze after chronically infusing rats implanted with minipumps with 
the drug aminophosphonovaleric acid (AP5, a competitive NMDAR antagonist), 
with saline infused and unoperated animals serving as controls.  As in the Morris 
(1981) study described above, rats were trained to find a hidden platform in the 
pool.  The first phase of training involved 15 trials; the inter-trial interval (ITI) was 
4 hours and escape latencies were measured.  Originally, AP5-infused animals 
learned the first location more slowly, but their performance was not statistically 
different from that of controls.  AP5-infused rats also exhibited an obvious non-
specific impairment (swim off the escape platform).  However, AP5-treated rats 
stabilized their escape latencies at the end of the training.  Then a transfer test 
was performed, the purpose of which was to find out how much had been 
learned about the spatial location of the platform.  Analysis of the paths during 
the transfer test showed that AP5-treated rats learned little about the location of 
the platform because they did not demonstrate spatial bias to the training 
quadrant.  Then animals were given 8 training trials with the platform back at the 
original location with 30-sec ITI, and, finally, on reversal trials rats were trained to 
swim to a new location.  During the reversal-training phase escape latencies of 
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rats both in the AP5 and control groups initially increased from 20 sec on the last 
trial block of original training to 60 sec on the first block of reversal training trials.  
As training proceeded, performances of rats in both groups improved but controls 
appeared to learn the new position at a faster rate than the AP5 treated rats did, 
again suggesting that AP5 impaired place learning.  Additionally, visual-
discrimination task was performed using two visible platforms, one with vertical 
and the other with horizontal stripes.  One of the platforms provided escape from 
the water, and black curtains that surrounded the perimeter of the pool to 
eliminate extra-maze cues.  This test showed that rats in all groups were similar 
in terms of their abilities to learn a visual discrimination task.  Morris et al. (1986) 
concluded that secondary sensorimotor and motivational impairment would 
unlikely be a cause of the place-learning deficits observed in AP5-infused rats. 
As with central administration of the competitive NMDAR antagonist AP5, 
systemic administration of non-competitive and competitive NMDAR antagonists 
have been found to impair performance of rats on numerous behavioral tasks 
designed to assess learning and memory (Danysz, Wroblewski, and Costa, 
1988; Heale and Harley, 1990; McLamb, Williams, Nanry, Wilson, and Tilson, 
1990; Parada-Turska and Turski, 1990; Wozniak et al., 1990, Caramanos and 
Shapiro, 1994).  One important issue that has been raised recently, however, is 
that NMDAR antagonists are known to produce numerous behavioral, non-
cognitive effects.  In particular, high doses produce such grossly observable 
changes in behavior such as peculiar rolling and circling, head weaving, 
increasing in locomotion, stereotypes, or ataxia, impairments in sensory 
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processing (Ahlander, Misane, Schott, and Ogren, 1999; Cory-Slechta, 1994).  
Therefore, it is crucial that researches apply the most sophisticated methods for 
dissociating learning and memory deficits caused by NMDAR antagonists from 
nonspecific behavioral effects. 
GABAA Agonist Effects on Spatial Learning 
Though their pharmacological mechanisms are fundamentally different, 
benzodiazepine drugs produce effects on spatial learning tasks that are similar to 
those produced by NMDAR antagonists.  The first attempt to study spatial 
learning in the water maze under a benzodiazepine (chlordiazepoxide) in rats 
was reported by McNaughton and Morris (1987).  Rats were placed in the pool, 
one trial per day, and were required to find a hidden platform and then, after 
thirteen trials of such training, a probe trial with the platform removed was given 
to test the extent to which changes in performance depended on knowledge of 
the spatial location of the platform.  Path length data were used, since latency to 
escape could be contaminated by changes in swimming speed (due to muscle 
relaxant properties of CDZ).  In contrast to previous results with the radial arm 
maze, data in this study indicated that 5 mg/kg CDZ can produce an impairment 
in spatial acquisition of the platform location in the swimming pool.  In contrast to 
the effects of hippocampal lesions (Riedel et al., 1999; Brooks, Cory-Slechta, 
Murg, and Federoff, 2000; Morris, Garrud, Rawlins, and O'Keefe, 1982), drug-
treated rats showed clear improvements in spatial navigation throughout the 
acquisition.  Additionally, performance on the probe trial detected no bias in 
choosing the quadrant and tendency to swim directly towards a particular distal 
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stimulus in CDZ-treated rats.  This observation led the authors to idea that 
deficits are related to pure impairment of spatial localization (McNaughton and 
Morris, 1987). 
Researchers employing various behavioral paradigms have studied 
effects of benzodiazepines on spatial behavior and, in general, the hypothesis 
that BZDs impair learning has been supported (Broekkamp, Pichon, and Lloyd, 
1984; Ferguson and Paule, 1993; Cole and Michaleski, 1986; McNaughton, 
1985; McNamara and Skeleton, 1991).  
A strong challenge to the view that NMDAR antagonists and GABA 
agonists impair learning and memory while sparing general performance abilities 
was brought by Cain's (1997) and of Saucier, Hargreaves, Boon, Vanderwolf, 
and Cain (1996) findings.  Cain (1997) rejected the idea that the impairment of 
spatial navigation observed after diazepam administration can only be due to 
learning disturbances.  In Cain’s (1997) experiment, prior non-spatial pretraining 
eliminated impairments in water maze learning caused by diazepam.   
Basically, Cain (1997) had two groups of animals tested on hidden-
platform-task and given the same range of diazepam doses with the only 
difference that one of them had received non-spatial pretraining and the other 
one had not.  Pretraining sessions involved letting rats swim to an escape 
platform that is moved to a new location on each trial.  Black curtains around the 
pool eliminated any cues that rats could have being using to navigate to the 
platform.  The procedure was therefore considered "non-spatial" pretraining 
because the position of the platform was never correlated with spatial cues in the 
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surrounding. Two non-drugged groups (naïve and pretrained) were also studied.  
The critical finding of Cain's study was that diazepam did not disrupt navigation to 
the hidden platform in pretrained rats whereas behaviorally naïve rats were 
severely impaired by diazepam.  Furthermore, Cain reported that diazepam 
caused behaviorally naïve rats to spend more time swimming in the periphery, to 
swim off, or over, the hidden platform, and produced ataxia on a beam-task.  
Such sensorimotor disturbances were not apparent in non-spatially pretrained 
rats.  Interestingly, behaviorally naïve rats that were tested on the visible-platform 
task rather than the hidden-platform task were not impaired relative to placebo 
treated controls or pretrained rats. 
The findings cited above were paralleled by those of Saucier et al. (1996) 
with NMDA and muscarinic cholinergic antagonists suggesting that visible 
platform task can serve as a control for groups that exhibit pronounced 
sensorimotor disturbances but the absence of a deficit on this task does not 
guarantee that a naïve drug group is free of subtle sensorimotor dysfunctions 
that can affect acquisition during the hidden-platform task. 
In summary, doses of both NMDAR antagonist and GABA agonist that 
produced marked non-specific disturbances and acquisition impairments in naïve 
rats did not produce these in subjects that received non-spatial pretraining.  
Thus, according to Cain, occupation of receptors by these drugs does not 
interfere with spatial learning in the Morris water maze and glutamate and GABA 
neurotransmitter systems may not be involved in spatial learning (Cain, 1997).  
The story of whether GABAA agonists and NMDAR antagonists can affect 
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learning and memory at doses that do not affect general behavioral performance 
was incomplete, however, because a narrow range of doses was studied by Cain 
and his colleagues.  Thorough dose-effect curves should provide a more 
complete picture of how drugs in these classes affect learning. 
Repeated Acquisitions Procedures in Behavioral Pharmacology 
One procedure that allows researchers to compare drug effects on 
acquisition and performance is the multiple-component, repeated-acquisition 
procedure (RAP).  The original RAP procedure introduced by Thompson and 
Moerschbaecher (1979) was situated in a traditional operant arrangement and 
involved teaching subjects patterns of reinforced keypeck or leverpress 
responses.  In the presence of one stimulus (e.g., a tone), a fixed response 
sequence, or pattern, is always effective (performance component).  In the 
presence of another stimulus (e.g., a light), the reinforced response pattern 
changes each session (acquisition component).  In this procedure, within a single 
experimental session, researchers can study drug effects on a well-learned 
sequence and compare them directly with the acquisition of a new sequence.   
The effects of phencyclidine (PCP) and pentobarbital (PB) on the 
acquisition and performance of the conditional discriminations in monkeys were 
studied by Moerschbaecher and Thompson (1980).  In each of two components 
of a multiple schedule, monkeys were required to respond on a right or left lever 
depending upon the stimulus combination (a color and geometric form).  
Reinforcement of a response in the presence of one stimulus (the form) was 
conditional upon the other stimulus (the color).  In the performance component of 
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the multiple schedule the discriminative stimulus (a combination of color and form 
stimuli) for lever presses was the same from session to session.  In the 
acquisition component, unlike the performance component, the discriminative 
stimuli changed every session.  The completion of a two-member chain of 
discriminations produced a food pellet.  The task components alternated after 50 
reinforcers were obtained or 25 min had elapsed, whichever occurred first.  The 
drugs (PCP and PB) were administered intramuscularly (im) 5 min prior the 
session.  Drug sessions were separated by five days, during which baseline and 
control sessions were conducted.  The data were analyzed in terms of  (a) the 
overall response rate (total responses/min, excluding timeouts) and (b) the 
overall accuracy or percent errors ((errors/total responses) x 100).  The data for 
each individual subject were analyzed by comparing a given drug session with 
the control range of variability (saline sessions).  Under this schedule both drugs 
produced a dose-dependent decrease in the overall rate of responding in 
comparison to saline controls.  At the highest doses studied, both drugs 
disrupted accuracy under both the acquisition and performance components. At 
lower doses, however, each drug produced selective effects on accuracy.  PCP 
selectively impaired accuracy (percent errors) at 0.056 - 0.1 mg/kg and PB 
selectively impaired accuracy at the dose of 5.6 mg/kg.  Generally, errors 
increased in the acquisition component at lower doses than those required to 
disrupt behavior in the performance component (Moerschbaecher and 
Thompson, 1980).  These results suggest that, at least under the conditions 
studied by Moerschbaecher and Thompson (1980), some PCP and PB doses are 
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both capable of disrupting mechanisms that enable learning and memory without 
interfering with processes that support general performance.                          
The RAP procedure also has been adapted to procedures that involve 
spatial navigation learning.  Specifically, Keith and Galizio (1997) used a 
multiple-component, repeated-acquisition procedure in the Morris water maze.  In 
the original procedure, developed by Morris (1981) the issue of distinguishing 
drug effects on learning versus performance was represented by carrying out 
hidden platform task versus visible platform task.  The visible platform task 
served as a control for effects of drugs and brain lesions on general performance 
variables.  Baring impairment on the visible platform tasks, researches have 
interpreted rodents' performances on a hidden platform task as a relatively pure 
measure of spatial learning (Morris, 1981; Morris et al., 1986).  As mentioned 
above, NMDAR antagonists and GABAA agonists impaired spatial learning 
(behavior on the hidden task) at doses that did not impair visible platform 
performance.  However, after Cain's findings, these interpretations have been 
questioned in terms of their ability to distinguish effects of drugs on learning 
versus performance.   
To distinguish drug effects on performance factors from effects on 
mechanisms specific to learning, Keith and Galizio (1997) trained rats to swim to 
a hidden escape platform in two different pools.  In one pool the platform always 
remained in the same location (performance).   In the other pool, the platform 
was moved to a new location for each session (acquisition).  The pools were 
painted different colors (back versus white) and surrounded by distinctively 
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different extra-pool cues to make them discriminable to the rats.  After stable 
baselines for both components were achieved, the effects of DZP and CDZ were 
studied.  DZP doses tested were 0.05, 0.075, 0.1, 0.2, and 0.3 mg/kg.  CDZ 
doses studied were 0, 10, and 30 mg/kg.  Drug or saline injections were given ip 
twice per week.   
Keith and Galizio found that dizocilpine increased latencies in the 
acquisition component in a dose-dependent manner with comparable 
impairments in the performance component.  Therefore, the selectivity of DZP on 
learning versus performance components was not found.  The dose-response 
functions for CDZ were quite different from those seen with DZP.  There was 
evidence of selective effect of this drug on acquisition.  A 10 mg/kg CDZ dose 
increased latencies in the acquisition component but not in performance.  Thus, 
Keith and Galizio concluded that their results contradicted the hypothesis that 
NMDA antagonists selectively disrupt processes involved in acquisition but were 
in agreement with common finding that BZDs impair acquisition of new behaviors 
but not performance of established ones (Keith and Galizio, 1997). 
A more recent study by Keith, Pitts, Pezzuti and Galizio (2003) further 
demonstrated the utility of the RAP procedure in the swimming pool as a way for 
differentiating drug actions on acquisition and performance components.  In this 
study the effects of three GABA modulators were evaluated: midazolam, 
chlordiazepoxide (both benzodiazepines), and pentobarbital (a barbiturate).  
Procedures similar to those used by Keith and Galizio (1997) were employed.  
However, only one pool was used for both performance and acquisition training.  
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The curtains that encompassed the perimeter of the pool were configured 
differently for the two task components.  The dependent variables of swim path 
ratio, escape latency, and average swim speed were analyzed (for details see 
Keith et al., 2003).  The researchers found that MDZ, CDZ, and PB all affected 
these variables in dose-dependent fashion.  The important difference between 
two subtypes of GABAA agonists emerged: both benzodiazepines produced 
evidence of selective disruption of acquisition at doses that did not disrupt 
performance.  The barbiturate, pentobarbital, however, produced acquisition 
impairment only at doses that also affected performance dependent variables 
(Keith et al., 2003). 
In summary, studies that used repeated acquisitions procedures provided 
direct comparison of drug effects on acquisition and performance.  Operant 
studies suggested that both NMDAR antagonists and GABA agonists produce a 
selective impairment of the acquisition component (Moerschbaecher and 
Thompson, 1980).  On the other hand, studies that used modified version of RAP 
procedure in the spatial navigation task suggest that GABAA agonists but not 
NMDAR antagonists can disrupt the behavior in the acquisition component at the 
doses that do not affect general performance (Keith and Galizio, 1997). 
Interactions between Pharmacological Systems that Influence Spatial Learning 
Evidence is now emerging that some diseases of the central nervous 
system that cause learning and memory impairment interfere with the normal 
functioning of multiple neurotransmitter systems, including glutamate, GABA, and 
acetylcholine (Cain, Ighanian and Boon, 2000; Rush, 1988; Wozniak et al., 
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1990).  One way to investigate functional relationships between multiple 
neurotransmitter systems and behavior is to characterize differences in 
behavioral effects produced by drugs from two different classes given individually 
and in combination with one another.  
A recent study by Cain et al. (2000) investigated the interactions between 
drugs that act on glutamate, GABA, and muscarinic cholinergic receptor systems.  
Cain et al. (2000) studied spatial learning in the Morris water maze by giving 
injections of the following agents: NPC17742 (a competitive NMDAR antagonist), 
scopolamine (muscarinic cholinergic receptor antagonist), and diazepam (GABA 
agonist) alone and in NPC-scopolamine and diazepam-scopolamine 
combinations. 
In the Cain et al. (2000) study, one group of rats was pretrained (as 
described on page 9) and the others were behaviorally naïve prior to drug 
testing.  The effects of 3.0 mg/kg NPC dose, 3.0 mg/kg diazepam dose, and 0.5 
mg/kg scopolamine dose were studied alone and in combination.  The 
experiment included the following groups: naïve scopolamine, pretrained 
scopolamine, naïve NPC, pretrained NPC, naïve diazepam, pretrained 
diazepam, naïve scopolamine + NPC, pretrained scopolamine + NPC, naïve 
scopolamine + diazepam, pretrained scopolamine + diazepam, naïve and 
pretrained controls. After place navigation testing with the submerged platform 
the rats received ten trials with visible platform as a control measure of non-
associative effects of drugs on performance.   
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The main findings reported by Cain et al. (2000) were that: 1) separate or 
combined administration of drugs to naïve rats substantially impaired acquisition 
of water maze task strategies and learning the location of the hidden platform, 2) 
pre-trained rats given a single drug used appropriate behavior and learned the 
hidden platform location as quickly as controls; 3) pre-trained rats given the NPC-
scopolamine and diazepam-scopolamine combinations used appropriate 
behavior to navigate but failed to learn the location of the hidden platform.  The 
fact that pre-trained rats have used the appropriate behavioral strategy was 
apparent from the improvements in the search time on the hidden platform task.  
The conclusion that they learned the location of this platform after receiving a 
single drug was obvious after moving the submerged platform to a different 
location and observing rats swimming in tight loops centered on the former 
location.    
The overall pattern of results was consistent with previous findings from 
Cain's group: poor performance of naïve rats was associated with an increased 
incidence of behavioral strategy impairments (Cain et al., 2000).  Pretraining 
(experience with task-specific behaviors) eliminated drug-induced behavioral 
strategy impairments.  Based on that, Cain and his co-workers concluded that for 
rats familiar with the required strategies, muscarinic cholinergic, NMDA, and 
GABAA receptor systems are, individually, not essential for robust place learning 
in the water maze (Cain et al., 2000). 
Similar studies have been carried out using operant procedure.  To 
directly compare drug actions alone and in combinations on learning versus 
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performance Thompson and Moerschbaecher (1981) used the RAP procedure in 
the operant chamber with patas monkeys.  As their previous results showed, 
when administered alone phencyclidine and pentobarbital generally decreased 
the overall response rate in the dose-dependent manner.  At higher doses, the 
percent errors increased and the performance component tended to be less 
sensitive in terms of accuracy than the learning component (Thompson and 
Moerschbaecher, 1980).    
Thompson and Moerschbaecher, (1981) extended their previous study by 
investigating how these agents affected repeated acquisitions when the drugs 
were combined.  Subjects were trained on a four-response chain by pressing the 
correct key in the presence of each of four geometric forms.  During the 
performance component the four-response chain remained the same from 
session to session, whereas for the learning component it was changed every 
session.  A steady state of repeated acquisition was established before initiating 
the drug study.  The data were analyzed in terms of (a) the overall response rate 
and (b) the overall accuracy or percent correct.  The order for giving drugs was 
as following: 1) the doses of PCP were tested in a mixed order with two 
determinations of each dose; 2) next, 3 mg/kg of PB was administered alone; 3) 
varying doses of PCP  (in a mixed order again) were tested in combination with 
the 3 mg/kg dose of PB; 4) 3 mg/kg of PB was administered alone then.  Then, 
using the same procedure, a higher dose of PB, either 7.5 or 10 mg/kg, was 
tested alone and in combination with varying doses of PCP.  Finally, the dose-
response curves for PCP alone were re-determined. 
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The higher doses of NMDAR antagonist and GABA agonist, when 
administered alone, again decreased the overall response rate and increased the 
percent errors in the both components of multiple schedule. The acquisition 
component was disrupted in that monkeys began making errors at smaller doses 
than were required to disrupt the performance component.  When PCP was 
administered in combination with PB, the NMDAR antagonist dose-response 
curves for both accuracy and rate of responding were shifted progressively to the 
left as the dose of GABA agonist was increased.  Since the original effect of PCP 
alone was replicated after PCP- PB combinations, it was clear that the shift 
couldn't be attributed to the development of sensitization to NMDAR antagonist.  
The authors concluded that the most reasonable explanation for this shift would 
be that pentobarbital "potentiated" the effects of phencyclidine, that is, 
combinations of NMDAR antagonist with GABA agonist consistently produced 
greater rate-decreasing and error-increasing effects than expected from simple 
addition of the effects of each drug given alone (Thompson and 
Moerschbaecher, 1981). 
These results were consistent with a subsequent study reported by 
Thompson and Moerschbaecher (1982) in which pigeons were subjects.  The 
task was that three response keys were illuminated at the same time by one of 
four colors and the animal was to acquire a four-response chain by pecking the 
correct key in the presence of each color.  The order of injections was the same 
as in the previous study.  The general results of this study were in agreement 
with study on monkeys described above.  It appeared that phencyclidine-
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pentobarbital combinations produced supra-additive effects on operant behavior 
in pigeons and patas monkeys (Thompson and Moerschbaecher, 1982).  
Somewhat different results emerged from the study of effects of NMDAR 
antagonist - GABA agonist (PCP and PB respectively) combinations on 
schedule-controlled behavior in the squirrel monkeys by Chait and Balster 
(1978).  Animals leverpressed under variable schedule (starting with FR 1, then 
moving to VI 15 and, later, gradually increasing the interval to VI 100).  No 
evidence was found for the hypothesis that NMDAR antagonist enhances the 
disruption of responding produced by GABA agonist.  In fact, most combinations 
in this study yielded rates of responding higher than expected based on additive 
effects.  Chait and Balster (1978) concluded that less disruption of responding 
occurred than would be expected based on simple addition of the effects of each 
drug given alone, i.e. the two compounds antagonized one another.  
In summary, experiments that investigated the effects of NMDAR 
antagonist-ACh antagonist and GABAA agonist-ACh antagonist on spatial 
learning and memory (Cain 2000) suggest that simultaneous blockage of the 
systems can cause failure of learning.  The studies based on chain-response are 
inconsistent in terms of their findings.  Some experiments indicate that combined 
administration of NMDAR antagonist-GABAB agonist produces "potentiated" 
disruptions (Thompson and Moerschbaecher, 1981; Thompson and 
Moerschbaecher 1982).  The others argue that PCP-PB combination would 
cause an impairment even less than expected from adding the effects of two 
agents administered alone (Chait and Balster, 1978). 
 21 
ACh Antagonist Effects on Spatial Learning 
Changes in acetylcholine-releasing neurons have been documented in 
patients with Alzheimer's disease (Coyle et al., 1983).  Thus, researchers have 
focused much attention on exploring the possibility that neuronal processes that 
depend upon acetylcholine are necessary for learning and memory.  In particular, 
the behavioral effects of centrally active muscarinic receptor blockers have been 
intensively investigated.  The important role played by cholinergic neurons in 
memory has been strengthened by the findings that ACh central agonists 
enhance recent memories and reverse learning deficits caused by anticholinergic 
drugs (Coyle et al., 1983).  Furthermore, the ACh blocker scopolamine has been 
shown to produce impairments in recent memories but spared immediate 
registration and long-term memory in young adult humans (Coyle et al., 1983). 
Similar to that, Savage, Faust, Lambert, and Moerschbaecher (1996) 
obtained evidence that scopolamine probably does not affect long-term memory 
storage but rather disrupts short-term memory processes.  Savage and his 
colleagues evaluated effects of scopolamine in monkeys responding under 
operant procedures designed to evaluate drug effects on learning and memory.  
In their procedure, responding was maintained by food presentation under a 
multiple-component schedule.  One component of the schedule was a repeated-
acquisition task in which the discriminative stimuli for left- and right-key 
responses changed each session (learning).  In the other component, the 
discriminative stimuli for responses were the same each session (performance).  
Doses of scopolamine ranged from 0.0032 to 0.032 mg/kg.  In both components 
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of the multiple schedule, scopolamine produced dose-related decreases in 
responding; there was little evidence of differential rate-decreasing effects 
between components.  Errors in learning increased in a dose-related manner, 
whereas percent errors in performance were generally unaffected except at high 
doses, which also produced substantial decreases in response rate. These 
results suggested that acquisition is more sensitive to the disruptive effects of 
scopolamine than is performance.   
The second procedure utilized repeated acquisition and delayed 
performance as a technique to study the effects of scopolamine on memory.  In 
this procedure, each session was divided into three phases: acquisition, delay, 
and performance.  Two different delays were studied.  After a 24-h delay, 
scopolamine had little or no effect on retention, accuracy or rate of responding.  
In contrast, after a 60-min delay, scopolamine decreased retention in a dose-
related manner. These data suggest that scopolamine produces a greater 
disruptive effect when short (60-min) delays intervene between training and 
testing than when long (24-h) delays intervene (Savage et al., 1996).  
Consistent with the previous finding that scopolamine produces selective 
deficits in short-term memory, Higgins, Woodward and Henningfield (1989) 
provided evidence that another anticholinergic drug, atropine, when administered 
to humans under RAP baselines, affected behavior in the acquisition component 
at lower doses than required to disrupt performance (Higgins et al., 1998).  
These results along with Savage et al. findings suggest selective nature of 
anticholinergic actions.   
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As mentioned above, Cain and his colleagues  (2000) found that after the 
administration of the 0.5 mg/kg dose of scopolamine to the rats all subjects 
performed as well as rats that were injected with saline.  Analysis of swim path 
patterns and qualitative observations of rats led authors to argue that rats 
learned the spatial location of the platform and retained the behavioral strategies 
required to perform the task.  However, when given the scopolamine-diazepam 
or scopolamine-NPC combination, the platform locations were no longer learned, 
although general performance was still spared (Cain et al., 2000).   
In contrast, other evidence suggests that the core action of scopolamine 
appears to be related to disrupting appropriate behavioral strategies.  Whishaw 
(1989) provided clues that it is likely that the main function of cholinergic system 
is to facilitate the selection of appropriately guided movements necessary to 
perform navigation tasks and that learning disruptions per se may be secondary 
to performance deficits.  In the same manner as Cain suggests in his study that 
muscarinic cholinergic activity may not be essential for robust place learning, 
Whishaw's results indicate that disruptions in the use of motoric skills contribute 
remarkably to the deficits produced by cholinergic blockade in spatial navigation 
task.  A number of aspects of rats' performance were examined in order to 
dissociate putative performance and learning deficits.   
In the initial studies in the water maze, Whishaw (1989) found that while 
cue response (strategies involved in swimming to the visible platform), position 
response (turning body left or right and then swim away of the wall), and place 
navigation retention (evaluating performance of previously learned tasks) were 
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unimpaired in rats subject to anticholinergic blockade, place navigation 
acquisition was impaired.  Rats were given various doses of atropine sulfate (0, 
10, 50, 100 mg/kg).  Subjects demonstrated impairments at doses as low as 10 
mg/kg, although reaching the control levels of performance after substantial 
training and showing that they did learn the platform location.  These results 
paralleled Cain's findings and raised a question of whether muscarinic cholinergic 
system is essential for the place response acquisition. 
To address this issue, Whishaw sought to determine whether the deficit 
was related to the place learning per se or it was related to the systems that are 
only indirectly involved in effective learning.  To do so, Whishaw carried out three 
experiments: one swimming place task and two dry-land tasks.  The swimming 
task required rats to locate a submerged platform in the pool.  The first dry-land 
task required rats to find a hole on the large circular platform from which they 
could escape to their cage; there were also several dark disks left on the 
apparatus to imitate the hole.  The second dry-land task employed the same 
circular apparatus, which was now covered by 2 cm of sawdust.  Rats were 
required to search for a food pellet, which was placed at specific location hidden 
under the layer of dust (rats were food deprived).  Thus, in all tasks the goal was 
to find a target that remained at the consistent location relative to distal room 
cues.   
Four trials per day were given for five days, then rats were given a probe 
trial on each of the tasks with the targets moved to a different location.  All three 
tasks were compared to the performance on the swimming cue task (visible-
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platform task).  Atropine-treated rats performed significantly worse than controls 
in all three tests in terms of escape latencies.  The observation of rats' behavior 
revealed that atropine-treated rats adopted different behavioral strategies than 
did controls.  These strategies employed either thigmotactic movements in the 
pool of water or, again, movements against the wall on the circular apparatus 
with rats’ backs arched and limbs extended.  These results indicated that 
impairment found previously in the water maze task was not specific but rather 
can be demonstrated in a variety of navigation tasks.  Whishaw's analysis 
revealed that atropine caused rats to adopt maladaptive motoric action patterns 
in each of the different tasks.  Interestingly, when these three tasks were studied 
in well-trained rats, their performances were not disrupted.   
The results of Whishaw's study demonstrated that naïve, atropine-treated 
rats were impaired on place acquisition tasks and that the impairments were 
likely due to subtle effects on motor patterns that can only be detected, Whishaw 
argued, by carefully observing the movements of the rats while they are 
performing the behavioral tasks used to measure learning (Whishaw, 1989).  
The picture of anticholinergic actions described in this section is 
ambiguous.  On one hand, some studies suggest that anticholinergic drugs 
produce selective learning/memory impairments in the chain-response RAP 
settings (Higgins et al., 1989; Savage et al., 1996). Other studies, however, imply 
that anticholinergic drugs cause motor impairments that interfere with the 
acquisition of new, but not previously learned, behaviors (Cain et al., 2000; 
Whishaw, 1989).  One of the experiments presented in this thesis was designed 
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to further investigate the effects of anticholinergis agent scopolamine on learning 
and memory.  
To summarize the literature reviewed above, data from the studies that 
employed serial chains suggest that compounds from all three classes produce 
selective action on non-spatial learning (Moerschbaecher and Thompson, 1980, 
Savage et al., 1996).  Studies based on spatial learning tasks by Cain et al. 
(2000), Keith and Galizio (1997), Whishaw (1989), and Keith et al. (2003), 
however, suggest that NMDAR and ACh antagonists and GABAA receptor 
modulators all can produce impairments on spatial learning tasks but that they 
produce their effects by disrupting different behavioral processes.  The Keith and 
Galizio (1997) study demonstrates evidence that GABAA agonists but not 
NMDAR antagonists can selectively impair spatial learning and memory.  
Findings from Cain et al. (2000) and Whishaw (1989) indicate that all three 
systems (GABAA, NMDA, and ACh) targeted alone may not be essential for 
spatial learning/memory processes and that manipulations with agents mostly 
affect motor functions necessary to perform the tasks. 
The experiments reported in this thesis were designed to reevaluate the 
effects of single compounds (dizocilpine, chlordiazepoxide, and scopolamine) on 
spatial learning and memory using the modified version of spatial navigation task.  
Additionally, no study has evaluated the simultaneous effect of NMDAR 
antagonist-GABA agonist and achetylcholinergic antagonist-GABA agonist on 
spatial learning in a water maze using multiple-component repeated-acquisition 
procedure.  To investigate whether these neurotransmitter systems are 
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interdependent, the present study used RAP procedure in a Morris water maze 
given neurochemical agents that target NMDA, GABA, and ACh systems alone 
and in combination.  
METHODS 
Subjects 
Subjects were four experimentally naïve, male Holtzman Sprague-Dawley 
rats (K3, K6, K8, and L4).  Each animal was individually housed under 12:12 hr 
dark-light conditions.  Food and water were available ad lib. 
Apparatus 
The apparatus was a circular white fiberglass pool (1.5 m diameter, 45.7 
cm deep) filled with 22.5 cm of water and a small white platform (10 cm diameter, 
20 cm high) that was submerged 2.5 cm below the surface of the water.  White 
non-toxic paint powder was used to make the water opaque.  The water 
temperature was maintained at 30° C ( ±2° C).  The room that housed the pool 
was 3m x 3m with white painted cinderblock walls.  The swimming pool was 
illuminated with two indirect halogen lights (500 Wt).  A digital camera was 
mounted to the ceiling directly above the center of the pool to view only the area 
of the pool.  Data from the camera were collected on a computer by running data 
acquisition software (Polytrack, San Diego Instruments) and included escape 
latency, total distance traversed, and pool quadrant entries.  The animals were 
observed during the trials on a monitor that displayed the camera's view. 
Experimental Variables 
The experiment in this thesis used a within-subject design with multiple 
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dependent and independent variables.  The dependent measures were escape 
latency, swim path ratio and swim speed.  Escape latency was measured in 
seconds from the time the subject is placed in the pool until it reaches the 
platform.  This dependent variable measures how much time it took rats to swim 
to the hidden platform.  The swimming speed was measured in centimeters per 
second.  This dependent variable captures the motoric aspects of the behavior 
and reflects how fast the rats’ swimming was.  Both escape latency and 
swimming speed are conventional measured often used in the studies 
investigation the effects of drugs on the spatial learning.  The swim path ratio, 
measured from release to escape, was the ratio of the difference between the 
actual swimming distance and the minimum possible distance from the release 
location to the escape platform.  This variable measures how accurate the path 
that the rat took was.  Swim path ratio was computed using the following formula: 
(AD-MD)/MD, where MD is the minimal distance and AD is the actual distance 
swam on the given trial.  A swim path ratio of zero indicated that the rat took the 
most direct route to the submerged platform.  In the present study, decreased 
latencies and swim path ratio within a training session were used to define 
learning. 
The independent variables included task component (performance or 
acquisition) and drug dose.  The task involved two components - performance 
and acquisition.  The performance component was designed to measure 
performance on a well-learned navigation problem.  The acquisition component 
was designed to measure the rate of learning about new platform locations.   
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There were several doses of the compound in each of the experimental 
study. Saline injections were also administered to control for possible effects of 
the injection procedure on performance. 
Preliminary Training 
Initially, animals had six trials per day (Monday through Friday) during 
which they were trained to swim to a submerged platform that was always 
located at the same place throughout training.  The curtain configuration that was 
used during training on the performance component is shown on the top panel of 
Figure 1.  Four release points that corresponded with the points where the 
curtains met were used.  The order of release location was determined prior to 
the beginning of the session in a pseudorandom manner.  Each release point 
was used at least once per session but never twice in a row.  To begin a trial, a 
rat was gently placed into the water facing the wall of the pool at one of four 
starting points and a stopwatch was started.  Once an animal stepped onto the 
platform the trial ended.  The subject was left on the escape platform for 15 s.  If 
a subject failed to find the platform by 60 s, it was led to the platform by 
experimenter.  Then a rat was returned to its home cage where it remained for 2-
min intertribal interval (ITI).  The sequence of start points was the same for each 
rat in the session but different from day to day.   
Preliminary training lasted until subjects met a criterion of three 
consecutive sessions with escape latencies for each session averaging less than 
10 sec per trial.    
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Figure 1.  Escape platform positions and stimulus arrangement used during 
multiple-component training. Top panel presents a platform position and stimulus 
arrangement during the performance component. Bottom panel presents platform 
positions and stimulus arrangements during the acquisition component. 
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Repeated Acquisitions Training 
Once animals met a criterion for preliminary training, they were moved to 
the repeated acquisitions training.  During this stage, subjects received six daily 
trials on each of two spatial navigation tasks.  During the performance 
component the submerged platform remained at the same location throughout 
training and testing.  The performance component was the same as during 
preliminary training.  During the acquisition component the submerged platform  
was moved to a different location on each day of training and testing but 
remained at the same place throughout a daily session.   
The arrangement of curtains that surrounded the pool during the 
acquisition component is shown on the bottom panel of Figure 1.  The sequence 
of platform positions was randomly determined with the constraint that the same 
position could not be used on consecutive days.  The eleven locations of the 
escape platform for acquisition component are shown on the bottom panel of 
Figure 1.    
For each rat, training trials were alternated between the performance and 
acquisition components.  Each training and testing session began with the 
performance component, and was followed by 2 min ITI and then a trial in the 
acquisition component.   
In order to meet a criterion for repeated acquisition training, rats' escape 
latencies had to be less than 10 sec per trial in the performance component for 
all six trials and less than 10 sec per trial in the acquisition task for trial 2-6 during 
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the final 10 sessions.  After reaching the criterion subjects entered the drug 
study.   
Throughout the drug study, injections were administered twice a week 
(Tuesday and Friday).  Average number of determinations for each dose and 
each animal was 3 (range 1-5 determinations).  The order at which doses were 
tested was semirandom.  The time period allowed to wash the tested compound 
out of the animal’s system after a particular experiment was conducted and 
before the next study began was one week. 
Experiment 1: Dizocilpine  
All four subjects received following doses of dizocilpine: 0.01, 0.03, 0.1, 
0.18, and 0.3 mg/kg.  The daily protocol for drug testing was the same as during 
baseline training.  Testing was conducted five days a week with Thursdays 
serving as control baseline sessions and the drug was administered on Tuesdays 
and Fridays.  An ip injection of DZP or vehicle was administered to the subjects 
30 min prior to the session.  
Experiment 2: Chlordiazepoxide  
All four subjects received following doses of chlordiazepoxide: 1, 3, 5.6, 
10, and 17 mg/kg.  The daily protocol for drug testing was the same as during the 
experiment 1. An ip injection of CDZ or saline was administered to the subjects 
15 min prior to the session. 
Experiment 3: Dizocilpine-Chlordiazepoxide  
All four subjects received the following combinations: 0 DZP-0 CDZ, 0.03 
DZP-1.0 CDZ, 0.03 DZP-3.0 CDZ, 0.1 DZP-1.0 CDZ, and 0.1 DZP-3.0 CDZ 
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mg/kg.   These doses of individual drugs were used in combination on the basis 
of pilot observation of the data obtained after administering dizocilpine and 
chlordiazepoxide alone.  Doses of DZP and CDZ that after administering alone 
produced either no effect or selective effect were chosen to test the combined 
action of drugs.  An ip injection was performed twice: the first injection contained 
dizocilpine and was given 30 min prior to the session, the second injection 
contained chlordiazepoxide and was given 15 min prior to the session (or 15 min 
after the first injection).  Double injections of saline served as a control and was 
given in the same manner (15 min apart, 30 and 15 min prior to the control 
session). 
Experiment 4: Scopolamine  
All four subjects received following doses of scopolamine: 0.03, 0.1, 0.17, 
0.3, 1.0, 1.7 mg/kg. The daily protocol for drug testing was the same as during 
the previous experiments. An ip injection of SC or saline was administered to the 
subjects 20 min prior to the session. 
Experiment 5: Scopolamine-Chlordiazepoxide  
Three subjects received following combinations (subject L4 died prior to 
this experiment): 0 SC-0 CDZ, 0.3 SC-3.0 CDZ, 0.3 SC-5.6 CDZ, 1.0 SC-3.0 
CDZ, and 1.0 SC-5.6 CDZ mg/kg.  An ip injection was performed twice: the first 
injection contained scopolamine and was given 20 min prior to the session, the 
second injection contained chlordiazepoxide and was given 15 min prior to the 
session (or 5 min after the first injection).  Double injection of saline served as a 
the control session). 
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Data Analysis 
Statistical analyses were conducted using the Statview statistical software 
package (SAS Institute, Cary, NC).  Repeated-measures ANOVAs were 
performed on each the dependent variable for each component.  In cases where 
raw distributions were severely skewed, data for escape latency and swim path 
ratio were log-transformed to normalize the distributions.  Unpaired t-tests were 
used as post-hoc tests to determine whether at specific doses differed 
significantly from those of saline sessions.  Bonferroni corrections (α/n, where α 
is .05 and n is the number of unpaired tests performed) were conducted to adjust 
the α level for multiple comparisons.  In addition to doing traditional analysis on 
the means of dependent variables on the different drug condition, the individual 
subject results were examined in detail.  Data on the dependent measures were 
plotted as a function of drug doses or trial number.  The hypothesis that 
chlordiazepoxide and scopolamine produce selective acquisition impairments 
would be supported in cases where a dose would produce reliably significant 
impairment of escape latency or swim path ratio in the acquisition, but not in 
performance, component.  The hypothesis that dizocilpine does not produce 
selective acquisition impairments would be supported in case in which a dose 
would produce reliably significant impairment of escape latency or swim path 
ratio in each of the components.  The hypothesis that dizocilpine-
chlordiazepoxide and scopolamine-chlordiazepoxide combinations produce 
overadditive effects would be supported if a combination produced greater 
disruption than expected from adding the effects of two doses when given alone. 
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RESULTS 
Preliminary Training 
 During preliminary training all four rats rapidly learned the first task 
component, the performance component.  The criterion for this training (three 
consecutive sessions with escape latencies for each session averaging less than 
10 sec per trial) was reached by all rats by the ninth session (range 3-9 sessions, 
M = 4.75).  Each animal then received six trials per day in the multiple-
component task (performance and acquisition).  Multiple-component training 
required 11-36 sessions (M = 21.5) for rats to reach the criterion (escape 
latencies had to be less than 10 sec per trial in the performance component for 
all 6 trials and less than 10 sec per trial in the acquisition task for trial 2-6 during 
the final 10 sessions) and move into the drug study. 
  Figure 2 shows mean escape latencies presented as a function of trial 
averaged across the last ten days before the drug studies began.  Open circles 
represent acquisition training latencies; closed squares represent performance 
training latencies.  It is evident that all four subjects had mastered the 
performance component and showed clear evidence of learning during the 
acquisition component.  Furthermore, the pattern obtained for swim path ratios 
during training was similar to the one presented for escape latencies.  
Figure 3 shows each individual rat’s escape latencies obtained for each 
animal during the last ten sessions before the drug treatment began.  Each panel 
of this figure represents the subject’s mean escape latencies for six trials for 
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Figure 2.  Mean escape latency during acquisition (open circles) and 
performance (closed squares) as a function of trials within last ten baseline 
sessions before drug study began. 
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Figure 3.  Individual mean subject escape latency during acquisition (open 
circles) and performance (closed squares) as a function of trials within last ten 
baseline sessions before drug study began. 
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both schedule components.  It is apparent that all four subjects learned the new  
locations during training on acquisition component at approximately the same 
rate, although animal K3 tended to fluctuate a bit more than the rest of the 
animals.  Nonetheless, K3’s latencies on the last acquisition trial were 
consistently shorter than on trials 1-5 during acquisition component.  Overall, the 
acquisition patterns were fairly consistent across all animals. 
Baseline Behavior   
After all subjects met the criterion required to enter the drug study, very 
stable behavioral patterns during both components were maintained throughout 
the study.  Figure 4 shows mean swim path ratios for all four subjects during 
baseline sessions performed on Thursdays.  Similarly, latency data are provided 
in Figure 5.  Both figures present data from each of the drug studies.  Both 
dependent variables under acquisition (open circles) and performance (closed 
squares) are reported as a function of a trial number.  It is apparent from both 
figures that escape latencies and swim path ratios were low in the performance 
component and relatively high on the first trial of the acquisition component.  
Additionally, a within-session decline in acquisition component is apparent for 
both of the dependent variables. 
Experiment 1: Dizocilpine  
Figure 6 presents the effects of DZP on three dependent variables: 
escape latency (top panel), swim path ratio or SPR (middle panel), and swim 
speed (bottom panel).  The closed squares represent group means on the 
performance component (all six trials of each session were analyzed) and 
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Figure 4.  Mean swim path ratio during acquisition (open circles) and 
performance (closed squares) as a function of trials within drug baseline 
sessions (Thursdays). DBL sessions were followed by a drug testing session on 
the next day.  Bars indicate standard error of the mean.  Panels present: 
dizocilpine DBL (top left), chlordiazepoxide DBL (top right), dizocilpine-
chlordiazepoxide DBL (middle left), scopolamine DBL (middle right), and 
scopolamine-chlordiazepoxide DBL (bottom center). 
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Figure 5. Mean escape latency during acquisition (open circles) and performance 
(closed squares) as a function of trials within drug baseline sessions 
(Thursdays). DBL sessions were followed by a drug testing session on the next 
day.  Bars indicate standard error of the mean.  Panels present: dizocilpine DBL 
(top left), chlordiazepoxide DBL (top right), dizocilpine-chlordiazepoxide DBL 
(middle left), scopolamine DBL (middle right), and scopolamine-chlordiazepoxide 
DBL (bottom center). 
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Figure 6.  Mean escape latencies (top), swim path ratios (middle), and swim 
speeds (bottom) as a function of dizocilpine dose during acquisition (open 
circles) and performance (closed squares) components. Bars indicate standard 
error of the mean. 
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the open circles represent the group means under the acquisition component 
(trials two through six of each session were used to compute acquisition means).  
Three out of four subjects were exposed to six doses of dizocilpine:  Subject L4, 
however, did not receive the highest (0.3 mg/kg) dose of dizocilpine because he 
was severely impaired by the 0.18 mg/kg dose. 
It is evident that administration of dizocilpine disrupted behavior on the 
task in both components in a dose-dependent fashion.  No evidence of a 
selective acquisition impairment at a dose that spared performance was found; 
all doses that impaired acquisition also impaired performance.  The raw data 
from escape latencies and swim path ratios were highly positively skewed and 
were therefore unsuitable for analysis using parametric statistics.  The 
logarithmic transformation of the raw data from these two variables, however, 
produced normal distributions and the transformed data were analyzed using 
ANOVAs.  A repeated measures ANOVAs revealed effects of dose on acquisition 
for SPR [F(6,114)=11.049, p<.0001], escape latency [F(6,84)=12.632, p<.0001] 
0.1 mg/kg DZP dose was the lowest that produced consistent disturbances under 
both task components.  The 0.1 mg/kg dizocilpine dose produced significantly 
longer escape latencies relative to saline under both acquisition and 
performance(p’s<.0001), for SPR (p’s<.0001). The effect of the dose 0.18 mg/kg 
was found to be significantly different from that of saline under acquisition and 
performance for the escape latencies (both p’s<.0001), SPR (both p’s<.0001) 
and swimming speed (p<.0001 and p=.0003, respectively).  The effect of the 0.3 
mg/kg dose was found also to be significantly different from that of saline under 
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acquisition and performance for the escape latencies (both p’s<.0001), SPR 
(both p’s<.0001) and swimming speed (p<.0001 and p=.0003, respectively).  The 
effect of the 0.3 mg/kg dose was found also to be significantly different from that 
of saline administration under acquisition and performance for the escape 
latencies (both p’s<.0001), SPR (both p’s<.0001), and swimming speed (both 
p’s<.0001).  Individual subject raw escape latency data is available in the 
appendix E (raw data on all three dependent variables is available in the 
electronic version of the present thesis).  The trial-by-trial data shown in Figure 7 
revealed that the 0.1-0.3 mg/kg doses caused increases in both escape latencies 
and swim path ratios consistently on all six trials on the performance component.  
During acquisition component these doses caused a modest impairment that was 
reflected in both dependent variables.  It is clear, however, that the data points of 
the last two trials on acquisition after administering 0.1-0.3 mg/kg were never as 
good as those achieved under the 0-0.03 mg/kg DZP doses. 
Discussion 
 In agreement with previous findings (Keith and Galizio, 1997), dizocilpine, 
an NMDAR antagonist, impaired spatial navigation behavior in a dose-dependent 
manner.  But the doses that disrupted acquisition latencies also produced 
evidence of impairment in the performance component.  In fact, this effect was 
seen with all three dependent variables.  The 0.1 mg/kg dose produced a 
consistent impairment in both components.  It was also the smallest dose 
required to impair escape latencies (see Figure 8) and swim path ratios (see 
Figure 9) under both components in all four subjects.  In the study by Keith and 
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Figure 7.  Mean escape latencies during acquisition (top left) and performance 
(top right), swim path ratios during acquisition (bottom left) and performance 
(bottom right) components as a function of trials for all dizocilpine doses tested.  
Bars indicate standard error of the mean. 
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Figure 8.  Individual mean subject escape latencies as a function of dizocilpine 
dose during acquisition (open circles) and performance (closed squares) 
components.  Bars indicate standard error of the mean of all determinations at a 
dose. 
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Figure 9.  Individual mean subject swim path ratios as a function of dizocilpine 
dose during acquisition (open circles) and performance (closed squares) 
components.  Bars indicate standard error of the mean of all determinations at a 
dose. 
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Galizio, (1997), other doses of dizocilpine were tested using RAP protocol (0.1, 
0.2, 0.3 mg/kg).  In that study 0.2 mg/kg was the dose that, on average, 
produced impairment on both the performance and acquisition components of 
the spatial RAP task.   
Consistent with Keith and Galizio’s (1997) report, the present experiment 
demonstrates clearly that although dizocilpine produced general performance 
impairments, learning was nevertheless still apparent in the presence of relatively 
high DZP dose (0.1 mg/kg).  This evidence is apparent from Figure 7 that show 
trial-by-trial plots in which some extent of learning of a new spatial location still 
occurred although the acquisition rate decreased (Morris et al., 1986: Danysz, 
Wroblewski, and Costa, 1988; Heale and Harley, 1990; McLamb, Williams, 
Nanry, Wilson, and Tilson, 1990).   
Experiment 2: Chlordiazepoxide 
Figure 10 shows the effects of chlordiazepoxide on escape latency, swim 
path ratio, and swim speed averaged across four subjects.  The open circles 
represent the group means under the acquisition component (trials two through 
six) and the closed squares represent the group means under the performance 
component (all six trials).  CDZ impaired behavior in both components in a dose-
dependent manner.  As it was the case for dizocilpine, latency and swim path 
ratio raw data were transformed to a log scale.  Swim speeds, however, were not 
transformed.  Repeated-measures ANOVAs revealed significant effects of dose 
on acquisition for SPR [F(6,144)=5.466, p<.0001], escape latency 
[F(6,144)=20.624, p<.0001] and swim speed [F(6,144)=26.405, p<.0001], and on  
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Figure 10.  Mean escape latencies (top), swim path ratios (middle), and swim 
speeds (bottom) as a function of chlordiazepoxide dose during acquisition (open 
circles) and performance (closed squares) components. Bars indicate standard 
error of the mean. 
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performance for SPR [F(6,174)=6.552, p<.0001], escape latency [F(6, 
138)=23.171, p<.0001], and swim speed [F(6,174)=25.565, p<.0001].  Doses 0 
and 1.0 mg/kg produced no disruption at either performance or acquisition 
component on any of the dependent measures.  Figure 10 shows that the effect 
of the 3.0 mg/kg CDZ dose on escape latency did not reliably differ from those of 
saline (p=.2233 and p=.3973, respectively).  However, the 3.0 mg/kg dose was 
selective for two out of four subjects (K3 and K8), causing increases in escape 
latencies and SPRs during the acquisition but not the performance component 
relative to saline baseline (see Figure 11).  Figure 11 also indicates that although 
the dose 3.0 mg/kg selectively disrupted behavior of rats K3 and K8, this effect 
disappeared at the dose 5.6 mg/kg and then reoccurred in both subjects again at 
10 mg/kg.  On average, however, the effect of 10 mg/kg was found significantly 
different from that of saline administration under acquisition and performance on 
escape latencies (p=.0006 and p<.0001).  The dose 5.6 mg/kg produced a 
selective effect on escape latencies in one out of four subjects (L4), increasing 
significantly its acquisition but not performance latency value.  Nevertheless, on 
average this dose produced a significantly different effect from that of saline in 
the performance component (p<.0001) but not in the acquisition component 
(p=.0835).  So, overall, three out of four subjects showed a selective impairment, 
albeit at different doses.  The highest dose (17 mg/kg) further disrupted the 
behavior of all subjects under both components: the effect of 17 mg/kg was found 
statistically different from that of saline under both acquisition and performance 
on escape latencies (p’s<.0001).  Individual subject raw escape latency data is 
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Figure 11.  Individual mean subject escape latencies as a function of 
chlordiazepoxide dose during acquisition (open circles) and performance (closed 
squares) components.  Bars indicate standard error of the mean of all 
determinations at a dose. 
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available in the appendix F (raw data on all three dependent variables is 
available in the electronic version of the present thesis).   
The 5.6 mg/kg dose of CDZ did not affect swim ratios whereas the 10 and 
17 mg/kg doses increased averaged swim path ratio in both task components.  
The effect of 10 mg/kg of CDZ was significantly different from that of saline 
administration under acquisition and performance on SPR (p=.0012 and  
p=.0066, respectively).  The effect of the highest dose, 17 mg/kg, was  
significantly different from that of saline administration under acquisition and 
performance on SPR (p’s<.0001).   
Individual rat swim path ratio plots (Figure 12) indicate the different extent 
of path accuracy disruption in the experimental animals.  Swim accuracy of the 
subject L4 was selectively affected by the 5.6 mg/kg dose of CDZ; 3.0-5.6 mg/kg 
caused a selective impairment in the rat K8.  Rats K3 and K6’s accuracy, 
however, was never affected during acquisition component at the dose that did 
not disrupt their swim accuracy during the performance component. 
The 5.6 mg/kg dose of CDZ was the lowest dose that affected swim 
speed: it significantly decreased speed in the performance component (p=.0003) 
but produced no effect in acquisition component. Doses of 10 and 17 mg/kg of 
chlordiazepoxide significantly decreased swim speed in both components (all 
p’s<.0001) causing non-selective effect on this variable.  Interestingly, data 
presented as a function of trial (Figure 13) revealed that doses of 10 and 17 
mg/kg caused a remarkable increase in swim path ratio and escape latency on 
the first trial of the performance component.  Such effect on latencies appeared 
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Figure 12.  Individual mean subject swim path ratios as a function of 
chlordiazepoxide dose during acquisition (open circles) and performance (closed 
squares) components.  Bars indicate standard error of the mean of all 
determinations at a dose. 
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Figure 13.  Mean escape latencies during acquisition (top left) and performance 
(top right), swim path ratios during acquisition (middle left) and performance 
(middle right), and swim speeds during acquisition (bottom left) and performance 
(bottom right) components as a function of trials for all chlordiazepoxide doses 
tested.  Bars indicate standard error of the mean. 
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not to be due to changes in swim speed and state-dependency (see Figure 13), 
raising the possibility that the impairments caused by the high chlordiazepoxide 
doses during the performance component of the task may owe to retrograde 
amnesia. 
Discussion 
The main finding of this experiment replicates the results of Keith and 
Galizio (1997) and Keith et al. (2003) studies that used the same paradigm to 
study effects of chlordiazepoxide on spatial learning and memory.  In mentioned 
above studies, it has been a consistent experimental outcome that this GABA A 
agonist causes selective impairments of acquisition swim path ratios and escape 
latencies at doses that do not produce impairments in the performance or affect 
swimming speed.  In the study by Keith et al. (2003) six out of eight subjects 
showed this pattern but at the dose 5.6 mg/kg, although different degrees of drug 
sensitivity were noticed.  In the present study, three out of four rats were 
impaired during the acquisition component at the doses lower than those 
required to produce performance impairments.  Two rats were selectively 
impaired at the 3.0 mg/kg dose of CDZ, one rat was selectively impaired at the 
5.6 mg/kg dose.  
These results further confirm the previous findings in literature on 
benzodiazepines that drugs from this class impair learning of new behavior 
without disrupting performance of well-established behaviors (Broekkamp et al., 
1984, McNamara and Skelton, 1991, McNaughton, 1995).   Present experiment’s 
findings contradict the hypothesis of Cain’s (1997) study that benzodiazepines 
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suppress mechanisms involved in general performance of the task.  His study 
suggested the possibility that when general strategies used to perform the task 
are well established, benzodiazepines do not impair spatial learning.  In the 
present study all subjects received an extensive training on both components 
and stable baselines were obtained.  The chlordiazepoxide effects observed in 
the present study are unlikely to be a reflection of the sedative properties of 
chlordiazepoxide because such properties would have affected escape latencies 
or swim speed in both task components to an equal extent.  
 Another interesting finding of this experiment is revealed by studying trial-
by-trial plots that indicated that general performance-related processes are 
affected by the high doses of CDZ (10 and 17 mg/kg), but just on the very first 
trial.  When the data for these doses were averaged across all of six performance 
component trials it appeared that performance was generally impaired.  But a 
closer inspection of the data revealed that performance on trials 2-6 were 
unaffected, suggesting that the general performance processes that support 
behavior in this task were not disrupted.  One interpretation is that these 
chlordiazepoxide doses produced retrograde amnesia but did not impair 
acquisition processes.  Other laboratories have previously reported that 
benzodiazepine drugs can cause retrograde amnesia (Netter, 1988; Ott, Rohloff, 
Aufdembrinke, and Fichte, 1988). 
Experiment 3: Dizocilpine-Chlordiazepoxide  
Figure 14 shows the effects of DZP-CDZ dose combinations on the three 
dependent variables.  Swim speed data sets were not transformed, whereas  
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Figure 14.  Mean escape latencies (top), swim path ratios (middle), and swim 
speeds (bottom) as a function of dizocilpine-chlordiazepoxide dose combination 
during acquisition (open circles) and performance (closed squares) components. 
Bars indicate standard error of the mean. 
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escape latency and swim path ratio data sets were transformed logarithmically.  
Repeated-measures ANOVAs revealed significant effects of combination dose 
on acquisition for escape latency [F(5, 195)=5.035, p=.0002] and swim speed 
[F(5,195)=4.627, p=.0005], and on performance for escape latency [F(5, 
235)=9.397, p<.0001], and swim speed [F(5, 235)=9.313, p<.0001] but no effect 
of combination dose for SPR on acquisition [F(5,195)=1.971, p=.0851] or on 
performance [F(5,235)=.849, p=.5284].  Unpaired t-tests revealed that the 
combination of the highest doses of two compounds (0.1 DZP-3.0 CDZ) had a 
significantly different effect from that of saline-saline administration in both 
acquisition and performance on escape latencies (p=.0004 and p<.0001, 
respectively), on swim speed (p=.0004 and p<.0001, respectively), and swim 
path ratio in the performance component only (p=.0097).   
As can be seen from Figure 15, 0.1 mg/kg of DZP produced a substantial 
nonselective disruption of behavior when administered alone.  When 
administered in combination with 1.0 mg/kg of CDZ, however, the detrimental 
effects of DZP were abolished and latencies during the performance component 
were virtually identical to those obtained in saline-saline condition.  When the 0.1 
mg/kg of DZP was administered in combination with 3.0 mg/kg of CDZ, again, 
dizocilpine produced less behavioral disruption than when it was administered 
alone. 
As it is evident from trial-by-trial data shown in Figure 16, escape latencies 
and swim path ratios improved across the trials, demonstrating that substantial 
learning occurred under the acquisition component within individual sessions  
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Figure 15.  Mean escape latencies during acquisition (white bars) and 
performance (black bars) of selected dose of dizocilpine and chlordiazepoxide 
given alone and in combination. 
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Figure 16.  Mean escape latencies during acquisition (top left) and performance 
(top right), swim path ratios during acquisition (bottom left) and performance 
(bottom right) components as a function of trials for all dizocilpine-
chlordiazepoxide dose combinations tested.  Bars indicate standard error of the 
mean. 
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under each of the drug combinations. The performance component was 
generally undisturbed in terms of both latencies and SPR with the exception of  
under the highest combination (0.1 DZP-3.0 CDZ), which was slightly poorer than 
under the other drug combinations.  The graphs on acquisition trial-by-trial data 
for both latencies and SPR revealed that the values of 0.1 DZP-3.0 CDZ 
administration never quite reached those of the other dose combinations but did, 
nevertheless, show a substantial degree of within session improvement.  The 
individual mean subject escape latencies and swim path ratios as a function of 
DZP-CDZ dose combination are presented in the appendix of the present thesis 
(appendices A and B, respectively).  Additionally, individual subject raw escape 
latency data on chlordiazepoxide administration is available in the appendix G 
(raw data on all three dependent variables is available in the electronic version of 
the present thesis).   
Discussion 
The results of this experiment were surprising.  Based on previous studies 
by Thompson and Moerschbaecher (1981, 1982) we predicted that combined 
administrations of NMDAR antagonist and GABA agonist would interact in a 
synergistic manner where chlordiazepoxide would increase the behavioral 
impairment caused by dizocilpine.  Thompson and Moerschbaecher, however, 
studied the effects of simultaneous administration of phencyclidine and  
pentobarbital on performances and acquisitions of serial response chains.  They 
reported that phencyclidine dose-response curves shifted to the left (i.e., lower 
 61 
doses of phencyclidine were required to produce behavioral disruptions) when 
the NMDAR antagonist was administered in combination with the barbiturate.  
In contrast with Thompson and Moerschbaecher (1981 and 1982), Chait 
and Balster (1978) reported that combined administrations of PCP and 
pentobarbital disrupted behavior less than one would expect if the compounds 
interacted in an additive fashion.  The between-study differences could be due to 
different compounds chosen for these and the present studies and procedural 
between-task differences (navigation versus non-navigation), the type of 
reinforcement used (appetitive versus non-appetitive motivation), and between-
species difference (rats versus monkeys and pigeons).  
The results of the present study were clear.  When the 0.1 mg/kg DZP 
doses were given alone, behavior was consistently disrupted in all four rats on 
both the acquisition and performance components.  When 0.1 DZP doses were 
given in combination with 1.0 CDZ doses, behavior was never disrupted in any of 
the subjects in either task component (see Appendix A).  
Experiment 4: Scopolamine  
Figure 17 shows the effects of scopolamine on escape latency, swim path 
ratio, and swim speed.  Scopolamine impaired behavior in both components in a 
dose-dependent manner.  Data on escape latency and swim path ratio were 
transformed to a logarithmic scale to obtain normal distributions.  Repeated-
measures ANOVAs revealed significant effects of dose on acquisition for SPR 
[F(7, 273)=6.137, p<.0001], escape latency [F(7, 273)=9.304, p<.0001] and swim 
speed [F(7,273)=6.200, p<.0001], and on performance for escape latency 
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Figure 17.  Mean escape latencies (top), swim path ratios (middle), and swim 
speeds (bottom) as a function of scopolamine dose during acquisition (open 
circles) and performance (closed squares) components. Bars indicate standard 
error of the mean.  
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[F(7,329)=5.143, p<.0001], and swim speed [F(7,329)=8.573, p<.0001] but no 
effect on performance for SPR [F(7,3290=1.307, p=.3164].  It is clear from 
individual data (Figure 18) that scopolamine effects on the behavior of rats in the 
task varied greatly between subjects.  In terms of latencies, performance 
component of the rat L4 was affected at 0.17, 0.3, 1.0, and 1.7 mg/kg of 
scopolamine. K8’s performance was hardly affected at all even at 1.7 mg/kg.  
The performance latencies of K6 were affected on average at 1.7 and latencies 
of the animal K3 were increased at 1.0 and 1.7 mg/kg on the performance  
component.  Additionally, individual subject raw escape latency data on 
scopolamine administration is available in the appendix H (raw data on all three 
dependent variables is available in the electronic version of the present thesis).  
Figure 17 illustrates that on average, effects of 0.1 mg/kg (p=.0025), 0.17 mg/kg 
(p<.0001), 0.3 mg/kg (p=.0002), 1.0 mg/kg (p<.0001), and 1.7 mg/kg 
 (p<.0001) on latencies in the performance component were found significantly 
different from that of saline administration.  Acquisition component was affected 
only at the doses 1.0 mg/kg (p=.0018) and 1.7 mg/kg (p<.0001) suggesting non-
selective effect of scopolamine on escape latency.   
Figure 17 (middle panel) shows that scopolamine also impaired swim path 
ratios on the performance component at lower doses than it did on the 
acquisition component: effects of 0.3, 1.0, and 1.7 mg/kg (all p<.0001) during 
performance and effects of 1.0 and 1.7 mg/kg (p=.0062 and p=.0007, 
respectively) during acquisition were significantly higher than those when saline 
was administered.  Rats’ individual dose-response curves (Figure 19) show that 
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Figure 18.  Individual mean subject escape latencies as a function of 
scopolamine dose during acquisition (open circles) and performance (closed 
squares) components.  Bars indicate standard error of the mean of all 
determinations at a dose. 
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Figure 19.  Individual mean subject swim path ratios as a function of scopolamine 
dose during acquisition (open circles) and performance (closed squares) 
components.  Bars indicate standard error of the mean of all determinations at a 
dose. 
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only K6’s swim path ratio was selectively impaired (at 1.0 mg/kg) out of four 
experimental animals.   
Figure 17 demonstrates that administration of scopolamine had also 
caused non-selective disturbance of the swimming speed.  Although during 
performance component the speed was significantly lowered by doses 0.3 mg/kg 
(p=.0041), 1.0 mg/kg (p<.0001) and 1.7 mg/kg (p=.0003), acquisition component 
was affected only by 1.0 mg/kg (p<.0001).   
Discussion 
Present results contradict the findings from the chain-response studies 
that argued for the selective nature of anticholinergic agents.  Research  
published by Savage et al. (1996) and Higgins et al. (1989) on monkey and 
humans provided evidence that anticholinergic drugs, when administered under 
RAP procedure, disrupt the acquisition component at doses lower than required 
to disrupt the performance component.  In the present experiment, doses that 
produced impairments in the acquisition component also caused disruption of the 
performance.  The results of Experiment 4 appear to be in agreement with 
reports by Saucier et al. (1996), Cain et al. (2000), and Whishaw (1989).  These 
studies have produced evidence that cholinergic muscarinic antagonists do not 
block spatial learning but rather can disrupt appropriate strategies necessary to 
perform the task.  Data averaged across the subjects indicates that the 
performance component was impaired at as low dose of scopolamine as 0.1 
mg/kg, whereas the acquisition was affected at a higher dose (1.0 mg/kg).  Swim 
path ratios and swim speeds were affected in the same manner.   
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Together, these findings suggest that scopolamine altered elements 
(accuracy and speed) of the well established behaviors.  Indeed, the most 
consistent observation during this experiment was perseverance of rats when 
they received scopolamine in circling along the walls of the pool.  If in the 
beginning of the swimming rats’ activity was not reinforced by encountering and 
mounting the platform, the rest of the behavior during the trial often degenerated 
to in general ineffective patterns (swimming about the perimeter of the pool in the 
same direction).  Data plotted as a function of trial (Figure 20) indicate that new 
locations were never acquired by rats subjected to the doses 1.0 and 1.7 mg/kg 
of scopolamine.  
Experiment 5: Scopolamine-Chlordiazepoxide  
Figure 21 presents the effects of Scopolamine-CDZ dose combinations on 
the three dependent variables.  Data of only three out of originally four subjects 
were included in the analysis.  Escape latency and swim path ratio data were 
transformation to a logarithmic scale.  The repeated-measures ANOVAs revealed 
significant effects of combination dose on acquisition for SPR [F(5,120)=10.245, 
p<.0001], escape latency [F(5,115)=13.239, p<.0001] and swim speed [F(5, 
45)=14.947, p<.0001], and on performance escape latency [F(5,140)=10.568, 
p<.0001], and swim speed [F(5,55)=8.471, p<.0001] but no effect on 
performance for SPR [F(5,145)=1.038, p=.4464].  As Figure 21 demonstrates 
escape latencies were significantly higher than those of saline-saline 
administration during performance component only once – after 1.0 SC-5.6 CDZ 
combination (p=.0002).  During acquisition component latencies were higher after 
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Figure 20.  Mean escape latencies during acquisition (top left) and performance 
(top right), swim path ratios during acquisition (bottom left) and performance 
(bottom right) components as a function of trials for all dizocilpine doses tested.  
Bars indicate standard error of the mean. 
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Figure 21.  Mean escape latencies (top), swim path ratios (middle), and swim 
speeds (bottom) as a function of scopolamine-chlordiazepoxide dose 
combination during acquisition (open circles) and performance (closed squares) 
components. Bars indicate standard error of the mean. 
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administration of all four combinations: 0.3-3.0 (p<.0001), 0.3-5.6 (p<.0001), 1.0-
3.0 (p=.0024), and 1.0-5.6 (p<.0001).   
Swim path ratios were selectively disrupted only at the 0.3–3.0 mg/kg 
doses combination, after which only acquisition component’s ratio was 
significantly higher than that of saline-saline administration (p<.0001).  Further 
administration of the combinations significantly increased swim path ratios at 0.3-
5.6 (p=.0053), 1.0-3.0 (p=.0047), and 1.0-5.6 mg/kg (p=.0080) during the 
performance component and at 0.3-5.6 (p=.0004) and 1.0-3.0 mg/kg (p=.0046) 
during the acquisition component.   
Figure 21 shows that swimming speeds were selectively impaired only 
when the 0.3 SC-5.6 CDZ combination was administered, i.e. only acquisition 
speed was significantly lower than that after saline-saline administration 
p=.0014).  Further administration of 1.0 SC-3.0 CDZ and 1.0 SC-5.6 CDZ mg/kg 
significantly decreased swimming speed during both components (all p’s<.0001).    
Rats’ individual data suggest that escape latencies of the animal K3 only 
were selectively impaired at all four combinations (see Figure 22).  The behavior 
of the rat K6 was selectively disrupted at 0.3 SC-3.0 CDZ and 0.3 SC-5.6 CDZ.  
Administration of 0.3 SC-3.0 CDZ and 1.0 SC-3.0 CDZ selectively affected 
escape latencies of animal K8.  Additional results that include individual subject 
swim path ratios and the effects combinations presented as a function of trial are 
shown in the appendix of the present thesis (appendices C and D, respectively). 
Furthermore, individual subject raw escape latency data on scopolamine- 
chlordiazepoxide administration is available in the appendix I (raw data on all 
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Figure 22.  Individual mean subject escape latencies as a function of 
scopolamine-chlordiazepoxide dose combination during acquisition (open circles) 
and performance (closed squares) components.  Bars indicate standard error of 
the mean of all determinations at a dose. 
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three dependent variables is available in the electronic version of the present 
thesis).   
Figure 23 indicates that significant impairments of the performance 
component under 1.0-5.6 mg/kg doses combination suggest additivity of 
pharmacological interaction between the two compounds.  However, impairment 
of the acquisition component under this combination was yet more modest than 
that under 1.0 mg/kg of scopolamine alone.  Nevertheless, administration of 0.3-
3.0, 0.3-5.6, and 1.0-3.0 mg/kg produced a profound evidence for less than 
additive effect of psychopharmacological action of scopolamine and 
chlordiazepoxide in combination.  
Discussion 
Data described above suggest that simultaneous administration of 
chlordiazepoxide and scopolamine produced selective impairment across three 
tested combinations (0.3 SC-3.0 CDZ, 0.3 SC-5.6 CDZ, 1.0 SC-3.0 CDZ) but not 
in 1.0 SC-5.6 CDZ combination.  The effect additivity would predict that in all of 
these cases reliable performance disruption should occur because the doses of 
scopolamine that alone produced performance impairment (0.3 and 1.0 mg/kg) 
were paired with either no-impairment (3.0 mg/kg) or performance-impairment 
(5.6 mg/kg) dose of chlordiazepoxide.  Clearly, three out of four effects of 
combinations do not agree with such prediction.  Perhaps, it is more correct to 
say in this instance that the additive effect occurred in terms of acquisition 
latencies and less than additive effect occurred in terms of the performance 
latencies.  The last combination (1.0 SC-5.6 CDZ) suggests the reversed 
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Figure 23.  Mean escape latencies during acquisition (white bars) and 
performance (black bars) of selected dose of scopolamine and chlordiazepoxide 
given alone and in combination. 
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interpretation: less-than additive effect occurred during the acquisition 
component and the additivity effect occurred during the performance 
component.  The reasons for such effect in the results are not clear.  Most likely it 
indicates the fact of the pharmacological interaction that exists between the two 
neurotransmitter systems.  One can assume that possible explanation for such 
interaction may lay in the fact that these systems play different roles in spatial 
learning processes.   
 Overall, the outcome of this experiment is quite unique: the particular 
doses of the compounds from two different classes were found which caused 
unselective performance disturbance when given alone but produced a selective 
impairment in spatial learning when given simultaneously.  At this point it is safe 
to say that this effect warrants further investigation.  
GENERAL DISCUSSION 
 The Morris Swim Task is frequently used by neuroscientists to study 
spatial learning and memory.  Over the last two decades numerous studies have 
used this task to study the effects of various drugs on spatial navigation.  Initially, 
the general consensus among researchers was that certain drugs, such as 
NMDAR antagonist, cholinergic drugs, and GABAA agonists, can impair spatial 
learning at doses that do not disrupt general performance processes (Ahlander et 
al., 1999; Broekkamp et al., 1984; Danysz et al., 1988;McLamb et al.,1990; 
McNamara and Skelton, 1991 Morris et al., 1986).  Recent studies, however, 
suggest that conclusions reached regarding the effects of these drug classes on 
spatial learning in the MST may have been premature.  It is now clear that drugs 
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can disrupt performance in the Morris Swim Task by interfering with the general 
organization of rats’ behavior in the pool.  During the initial stages of training on 
the Morris Swim Task, typically rats primarily swim around the edge of the pool 
scratching at the wall.  When they do encounter the submerged escape platform 
during the early stages of training rats often swim over it or even jump off of it.  
Typically, as training proceeds these behaviors are replaced by behaviors that 
increase successful escape from the water. Such as swimming away from the 
pool wall and climbing on the escape platform when it is encountered.  Studies 
reported by Peter Cain and his colleagues (Saucier et al., 1996; Cain, 1997) 
show that NMDAR antagonists, GABAA modulators, and cholinergic drugs, when 
given to behaviorally naïve rats, cause the ineffective behavior patterns to persist 
longer then they do in non-drugged rats.  Furthermore, when given to 
behaviorally pretrained animals, the same drugs typically do not cause such 
sensorimotor impairments, and drug effects on spatial learning are diminished.  
To summarize, dose of NMDAR and cholinergic antagonists, and GABAA 
modulators that produced non-specific disturbances and acquisition impairments 
in naïve rats did not produce those in subjects that received pretraining. 
 The procedure used in the present thesis allows precisely such a 
comparison in the subjects that received extensive spatial learning.  The RAP 
methodology made it possible to determine whether the observed impairments in 
acquisition were due to the non-specific effects of compounds on general 
performance or if these compounds specifically cause the impairment of spatial 
learning.  Stable baselines on the non-drug sessions insured that the procedure 
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continuously maintained reliable performance behaviors and rapid acquisitions.  
Overall, throughout the present study the subjects demonstrated evidence of 
acquisition of a new location during baseline sessions.   
 Three experiments of the present thesis investigated the effects of a 
single drug administration on spatial learning and memory.  An important finding 
of the present study was the confirmation of the previous report by our laboratory 
relating to the effects of dizocilpine and chlordiazepoxide (Keith and Galizio, 
1997).  Keith and Galizio (1997) found that GABAA agonist but not NMDAR 
antagonist disrupts acquisition of a new spatial location at the doses that do not 
affect general performance. 
 It appears clear that the NMDA non-competitive receptor antagonist 
does not disrupt place learning without also producing general performance 
disturbances.  In agreement with the previous reports by our laboratory, results 
from dizocilpine manipulations contradict those obtained from the serial response 
chains (Moerschbaecher and Thompson, 1980; Thompson and Moerschbaecher, 
1981; Thompson and Moerschbaecher, 1982).  Generally, these studies 
suggested that NMDAR antagonists can produce learning impairments at the 
dose that spare ability to perform the task.  In our view, this contrast in obtained 
results can be explained by the between-task differences (spatial versus non-
spatial, positive versus negative reinforcement tasks), between-drug differences 
(competitive versus non-competitive NMDAR antagonists), and between-species 
differences (monkeys and pigeons versus rodents).   
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 The findings from the Experiment 1 contribute to the current reports on 
effects of NMDAR antagonists on spatial learning and corroborate Saucier et al. 
(1996) and Cain's (2000) reports that NMDAR antagonists do not impair learning 
of a new spatial location.   
 Another important outcome of this study was replication of the effects of 
GABAA agonist administration that was previously reported by our lab (Keith and 
Galizio, 1997; Keith et al., 2003).  In the present study three out of four subjects 
produced evidence of selective disruption of place navigation after manipulation 
with chlordiazepoxide.  The present results contradict Cain’s findings that after 
stabilizing general performance on the spatial navigation task, GABA agonists do 
not produce acquisition impairments in the pretrained animals.  Subjects in the 
present study were behaviorally stabilized before entering the drug study.  Thus, 
overall, the present findings support the evidence that came from research that 
also employed multiple-component RAP procedure.  These reports used the 
RAP procedure to study non-spatial acquisition of the response sequences.  
Research in the operant settings has consistently found that GABA agonists 
disrupted acquisition responses at the doses that did not disrupt performance 
responses (Moerschbaecher and Thompson, 1980; Thompson and 
Moerschbaecher, 1981; Thompson and Moerschbaecher, 1982).  The present 
results appear in agreement with the pattern of findings obtained in these 
studies. 
 Another intriguing result of the experiment on chlordiazepoxide was the 
evidence that suggested the possibility that high doses of CDZ (10 and 17 
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mg/kg) produced retrograde amnesia.  Human studies have shown that both 
antero- and retrograded amnesia are often observed as effects of 
benzodiazepine administration (Ott et al., 1988; Netter, 1988).  In the present 
study careful observation of data plotted as a function of trial revealed that under 
the highest doses of CDZ performance component was significantly disrupted on 
the first trial.  Thus, our understanding of the effects at these doses is currently 
limited and more research on that is needed to confirm whether this disruption 
reflects retrograde amnesia or non-cognitive sensorimotor disturbances. 
 To our knowledge, the present thesis reports the first attempt to 
investigate the effects of muscarinic cholinergic antagonist scopolamine under 
RAP procedure adapted to the Morris Swim Task.  In the manner similar to 
dizocilpine, the present data on scopolamine manipulations disagree with the 
studies that employed repeated acquisitions procedure to study the effects of 
scopolamine and atropine on serial response chains (Savage et al., 1996; 
Higgins et al., 1989).  These studies showed that both scopolamine and atropine 
impaired acquisition of response sequences at the doses that did not affect 
response accuracies during the performance component.  However, the 
evidence obtained in the Experiment 4 points in favor of non-selective nature of 
pharmacological action of scopolamine.  The results support the Whishaw's 
(1989) observations in which he found that scopolamine intervened with 
acquisition of effective behavioral strategies during the navigational task.  Data 
on scopolamine effects presented here demonstrated that the performance 
component was reliably affected by scopolamine at lower doses than those 
 79 
required to disrupt acquisition.  The present findings are also in agreement with 
Cain (1997) and Cain et al. (2000) reports in which the investigator was able to 
demonstrate that muscarinic cholinergic manipulations do not impair navigation 
to the hidden platform.  
 Overall, the data on a single drug administration presented here further 
contribute to the literature on effects of NMDAR and ACh muscarinic antagonists 
and GABA agonists. 
 The present thesis also makes one very important methodological 
addition in the field of testing the combined actions of different drugs.  To our 
knowledge this was the first study that looked at the effects of simultaneous 
administration of drugs from different classes using the benefits of the RAP 
methodology that were named above.   
 A great number of studies that are related to the problem of co-
administering numerous pharmacological agents are reported periodically.  
Studies on patients with neurodegenerative dementia frequently produce 
evidence of dysfunction in multiple (i.e., cholinergic, glutamatergic, 
benzodiazepine, and serotonergic) neurotransmitter systems, sometimes 
suggesting that simultaneous damage to the transmitter functioning constitutes 
such conditions (Cain et al., 2000).   
 The initial assumption for both experiments on drug combination was 
based on the results obtained by Thompson and Moerschbaecher (1981 and 
1982).  These two studies obtained the identical results with two species 
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(pigeons and monkeys): the effect of PCP administration was potentiated by PB 
administration and overall produced overadditive effect on learning.   
 The results of combined administration of NMDAR antagonist-GABA 
agonist (Experiment 3) differed from those of Thompson and Moerschbaecher, 
and therefore, did not support the hypothesis held before entering the drug 
combination study.  Findings of Experiment 3 resembled more the pattern 
obtained by Chait and Balster (1978) who also reported antagonism between 
NMDAR antagonist and GABA agonist.  Chait and Balster argued that less-than 
additive results could be attributed, among the other reasons, to the different 
species used in their and Thompson and Moerschbaecher’s studies (squirrel 
monkeys versus pigeons).  Chait and Balster also assumed the possibility of 
behavioral measure employed in their study (the rate of lever pressing for food 
presentation) being "not a suitable measure for detecting a drug interaction which 
manifests itself in other forms of behavior".  The between-species differences 
remain a valid reason for the divergent outcomes of the present and the 
Thompson and Moerschbaecher's studies (rats versus pigeons).  Additionally, 
between-task and between-drug differences are also plausible.   
 Generally, to determine whether effects of drug combination are 
additive, synergistic or antagonistic two requirements must be met.  First, the 
dose-response for each drug alone and combinations of the drugs must be 
obtained.  Second, one should have knowledge of what to expect in the case of 
additive drug effects.  According to Woolverton (1987), with respect to the 
second requirement there are two basic approaches that make prediction about 
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the additive outcome: a prediction based on dose addition and a prediction based 
on effect addition.  Dose addition is best conceptualized as the result of 
combining a drug with itself and it is clear that a drug is additive with itself.  On 
the other hand, effect addition is thought to exist when effect of the combination 
of two drugs is equal to the sum of the individual effects of each drug given 
alone.  In spite of the fact that each model is based on the comparisons of 
experimental results to predicted additive drug effects, the two approaches make 
different predictions of additivity.  In order to perform the quantitative analysis of 
drug interactions it is necessary to use isobolographic method (for details, see 
Woolverton, 1987).  To do so, one would need to conduct a greater number of 
determinations of each dose combinations.  Such analysis was beyond the scope 
and expertise of the present study.   
 Nevertheless, the finding of Experiment 3 is very important and worth to 
be explored with further thoroughness, namely, that impairment in both task 
components produced by 0.1 mg/kg DZP was abolished by the co-administration 
of 1.0 mg/kg CDZ to the saline-saline level.  The concept of effect-additivity 
predicts that combined effects of such combination would produce even greater 
deficit than 0.1 mg/kg did alone.  This was not the case.  Moreover, when 
combined with 3.0 mg/kg CDZ (which alone produced a selective impairment in 
half of the subjects), effects of the 0.1 DZP continued to be abolished.   
 In case of scopolamine-chlordiazepoxide combination the same less-
than additive pattern reoccurred.  The most significant outcome of Experiment 5 
was the finding of doses from two different classes that alone caused 
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impairments in both components but, when given together, produced a selective 
deficit.  The results of this study seemed to be in accord with Cain et al.'s (2000) 
report.  As shown by Cain and his colleagues, combined administration of 
scopolamine and diazepam spared behavioral strategies used by the rats in their 
experiment but blocked learning of a new platform location.  A single drug 
administration produced no impairment in either of these two elements. As the 
authors admit, the reasons for sparing the behavioral strategies are not clear.  
The possibility for such a pattern was attributed to the neurotransmitter systems 
interaction.  Interestingly, the implication made by Cain et al. was that 
potentiation happened between the two systems (Cain et al., 2000).  In this way, 
the present study makes a unique contribution to the assumptions behind the 
spared performance and impaired acquisition.  It follows from Experiment 5 that it 
was less-than additive pattern rather than potentiation (more-than additive) 
causing such outcome. 
 Another unique implication from Experiment 5 came as a result of using 
the procedure that allows a direct comparison of the drug effects on the behavior 
during the performance and acquisition components.  As was stated before, not 
“pure” less-than additive effect occurred at 0.3-3.0, 0.3-5.6, and 1.0-3.0 mg/kg 
doses combinations.  More precisely, a less-than additive effect occurred during 
the acquisition component and additive effect during the performance 
component.  With the highest doses in combination, the pattern was reversed.  A 
likely conclusion that follows from this finding can be that effect of interaction 
depends on the measured behavior.   It appears that the effects of drugs in 
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combination are different depending upon whether well-learned behavior or 
acquisition of a new information is measured. 
The conclusions that can be reached from the present study on drug 
interactions would be stronger if the original single-drug dose-response curves 
had been redetermined after the drug combinations have been studied to confirm 
that rats’ sensitivities to dizocilpine, chlordiazepoxide, and scopolamine did not 
change over the course of the experiments.  Nonetheless, the present thesis 
produced two novel findings that warrant further investigation.  First, the 
benzodiazepine, chlordiazepoxide, ameliorated the adverse effects of dizocilpine, 
an NMDAR antagonist, on spatial behavior.  Second, a cholinergic antagonist, 
scopolamine, amplified the disruptive effects of chlordiazepoxide on acquisition 
without causing an impairment in the general performance.  
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Individual mean subject escape latencies as a function of dizocilpine-
chlordiazepoxide dose combination during acquisition (open circles) and 
performance (closed squares) components.  Bars indicate standard error of the 
mean of all determinations at a dose. 
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Individual mean subject swim path ratios as a function of dizocilpine-
chlordiazepoxide dose combination during acquisition (open circles) and 
performance (closed squares) components.  Bars indicate standard error of the 
mean of all determinations at a dose. 
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Individual mean subject swim path ratios as a function of scopolamine-
chlordiazepoxide dose combination during acquisition (open circles) and 
performance (closed squares) components.  Bars indicate standard error of the 
mean of all determinations at a dose. 
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Mean escape latencies during acquisition (top left) and performance (top right), 
swim path ratios during acquisition (bottom left) and performance (bottom right) 
components as a function of trials for all scopolamine-chlordiazepoxide dose 
combinations tested.  Bars indicate standard error of the mean. 
SC-CDZ Acquisition Average Escape Latency
0
10
20
30
40
50
60
1 2 3 4 5 6
Trial
Es
ca
pe
 La
ten
cy
 (s
)
bl
0 x 0
0.3 x 3.0
0.3 x 5.6
1.0 x 3.0
1.0 x 5.6
SC-CDZ Performance Average Escape Latency
0
10
20
30
40
50
60
1 2 3 4 5 6
Trial
Es
ca
pe
 La
ten
cy
 (s
)
bl
0 x 0
0.3 x 3.0
0.3 x 5.6
1.0 x 3.0
1.0 x 5.6
SC-CDZ Acquisition Average Swim Path Ratio
0
10
20
30
40
50
60
1 2 3 4 5 6
Trial
Sw
im
 P
ath
 Ra
tio
bl
0 x 0
0.3 x 3.0
0.3 x 5.6
1.0 x 3.0
1.0 x 5.6
SC-CDZ Performance Average Swim Path Ratio
0
10
20
30
40
50
60
1 2 3 4 5 6
Trial
Sw
im
 Pa
th 
Ra
tio
bl
0 x 0
0.3 x 3.0
0.3 x 5.6
1.0 x 3.0
1.0 x 5.6
 94 
Appendix E 
 
 
 
Average of Latency     Component   
Rat Dose Date acquisition performance 
K 3 0 7/27/2001 5.64 2.15 
    8/24/2001 6.71 2.70 
  0.01 9/4/2001 5.53 2.03 
  0.03 8/17/2001 6.77 2.79 
    9/21/2001 5.48 1.47 
  0.1 8/28/2001 42.32 4.79 
    9/7/2001 8.35 2.12 
    9/11/2001 5.32 2.06 
    9/25/2001 48.15 18.95 
  0.18 8/14/2001 24.32 9.82 
    9/18/2001 49.07 30.49 
  0.3 8/10/2001 45.02 24.88 
  baseline 7/26/2001 5.88 2.05 
    8/9/2001 6.30 4.03 
    8/16/2001 7.19 2.84 
    8/23/2001 5.30 3.42 
    9/6/2001 5.34 1.94 
    9/20/2001 3.60 1.90 
K 6 0 7/17/2001 6.62 2.34 
    8/24/2001 7.47 2.45 
  0.01 9/4/2001 5.27 1.88 
  0.03 7/20/2001 3.82 2.25 
    8/17/2001 5.15 2.33 
  0.1 7/24/2001 4.86 2.04 
    8/21/2001 4.15 6.90 
    9/11/2001 13.77 2.90 
    9/21/2001 7.93 2.21 
    9/25/2001 59.91 14.49 
  0.18 8/14/2001 39.43 15.29 
    8/28/2001 19.21 3.09 
    9/14/2001 18.78 6.82 
    9/18/2001 48.15 5.27 
  0.3 7/27/2001 41.33 17.94 
  baseline 7/19/2001 6.04 1.99 
    7/26/2001 6.58 3.78 
    8/16/2001 6.53 8.31 
    8/23/2001 9.39 2.15 
    9/13/2001 6.88 2.38 
    9/20/2001 3.03 2.23 
K 8 0 6/22/2001 3.73 1.94 
    7/3/2001 3.39 2.15 
    8/24/2001 5.11 2.06 
    9/18/2001 2.13 2.01 
 95 
  0.01 8/28/2001 5.00 1.82 
    9/4/2001 4.80 1.75 
  0.03 7/13/2001 7.18 1.74 
    7/27/2001 2.84 2.84 
    8/17/2001 6.53 2.34 
    9/21/2001 5.40 1.93 
  0.1 7/10/2001 4.58 1.57 
    7/24/2001 4.00 2.08 
    8/21/2001 42.28 33.33 
    9/7/2001 5.69 1.74 
    9/11/2001 6.94 2.02 
  0.18 7/20/2001 9.45 8.84 
    8/14/2001 31.52 46.25 
    9/14/2001 8.12 4.95 
  0.3 6/29/2001 41.27 7.34 
    7/17/2001 11.61 7.36 
  baseline 6/21/2001 3.86 1.85 
    6/28/2001 7.18 1.91 
    7/5/2001 3.37 2.21 
    7/12/2001 3.92 1.94 
    7/19/2001 6.46 2.29 
    7/26/2001 2.59 2.61 
    8/16/2001 5.65 2.67 
    8/23/2001 4.31 2.00 
    8/30/2001 5.51 1.98 
    9/6/2001 4.02 1.80 
    9/13/2001 7.57 1.94 
    9/20/2001 4.27 1.86 
L 4 0 7/20/2001 3.83 2.48 
    8/28/2001 6.73 2.30 
    9/21/2001 3.70 2.33 
  0.01 9/4/2001 9.46 2.10 
    9/28/2001 4.65 2.13 
    10/5/2001 3.90 2.11 
  0.03 7/27/2001 3.71 2.36 
    8/17/2001 6.12 2.40 
    9/14/2001 5.37 2.44 
  0.1 7/24/2001 11.97 2.37 
    8/21/2001 49.90 51.21 
    9/7/2001 5.28 5.82 
    9/11/2001 5.64 2.78 
    9/25/2001 36.05 15.51 
  0.18 8/14/2001 38.64 50.47 
    8/24/2001 20.09 23.01 
    9/18/2001 25.71 29.60 
  0.3 8/10/2001    
  baseline 7/19/2001 4.23 2.49 
    7/26/2001 4.87 3.45 
    8/9/2001 3.60 2.37 
    8/16/2001 5.89 2.64 
 96 
    8/23/2001 5.19 3.32 
    9/6/2001 4.79 2.26 
    9/13/2001 3.36 2.75 
    9/20/2001 8.41 2.31 
    9/27/2001 6.37 2.45 
    10/4/2001 7.46 2.59 
    10/11/2001 5.82 2.86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Individual subject escape latency raw data of dizocilpine administration 
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Average of Latency     Component   
Rat Dose Date acquisition performance 
K 3 0 10/12/2001 5.85 1.96 
    10/23/2001 8.48 1.91 
    11/30/2001 4.68 2.13 
  1 11/6/2001 4.71 1.87 
    11/20/2001 5.04 2.11 
  3 10/16/2001 5.06 2.01 
    11/13/2001 18.47 2.54 
  5.6 11/2/2001 7.54 3.02 
    11/16/2001 4.26 2.91 
    11/27/2001 8.40 2.48 
  10 10/26/2001 7.59 3.35 
    12/4/2001 15.76 3.70 
  17 11/9/2001 13.89 13.31 
  baseline 10/11/2001 4.34 1.81 
    10/22/2001 5.88 1.96 
    10/25/2001 6.30 2.21 
    11/1/2001 3.67 1.86 
    11/8/2001 6.12 2.81 
    11/15/2001 5.68 2.11 
    11/29/2001 2.52 1.66 
K 6 0 9/28/2001 10.44 2.62 
    10/23/2001 4.17 2.62 
    11/30/2001 7.91 2.61 
  1 10/9/2001 4.96 2.61 
    11/16/2001 2.89 1.97 
  3 11/13/2001 10.05 2.42 
    11/20/2001 5.14 2.75 
  5.6 10/12/2001 6.83 3.28 
    11/2/2001 15.86 5.18 
    11/27/2001 7.76 3.80 
  10 10/26/2001 10.30 8.54 
    11/6/2001 5.00 7.19 
    11/9/2001 26.58 13.73 
  17 12/4/2001 13.57 14.73 
  baseline 9/27/2001 5.80 3.07 
    10/11/2001 8.82 2.94 
    10/25/2001 8.44 2.53 
    11/6/2001 8.04 3.29 
    11/8/2001 4.22 2.39 
    11/15/2001 9.82 2.41 
    11/29/2001 4.17 2.78 
K 8 0 10/23/2001 3.86 1.92 
    11/30/2001 4.38 2.09 
 98 
  1 10/9/2001 3.70 2.13 
    11/6/2001 3.57 2.14 
  3 10/16/2001 8.46 2.16 
    11/9/2001 12.24 2.30 
  5.6 10/12/2001 6.20 3.97 
    11/2/2001 6.79 3.24 
    11/16/2001 9.47 2.89 
  10 9/28/2001 3.86 2.66 
    10/26/2001 16.51 3.72 
    11/13/2001 14.96 3.25 
  17 10/5/2001 37.81 8.46 
  baseline 9/27/2001 9.62 1.87 
    10/4/2001 6.31 1.98 
    10/11/2001 2.78 2.10 
    10/25/2001 4.87 2.03 
    11/8/2001 3.92 2.21 
    11/15/2001 5.63 1.98 
    11/29/2001 2.91 1.92 
L 4 0 10/12/2001 4.21 2.94 
    10/23/2001 6.58 2.54 
    12/8/2001 6.71 2.90 
  1 11/6/2001 3.68 2.41 
    11/20/2001 4.81 2.15 
  3 10/16/2001 4.71 2.70 
    11/13/2001 3.70 3.21 
  5.6 11/2/2001 6.62 3.17 
    11/16/2001 14.52 3.25 
    11/27/2001 15.26 3.69 
  10 10/26/2001 6.56 5.77 
    12/21/2001 16.16 8.86 
  17 11/9/2001 19.55 7.02 
    12/18/2001 39.07 30.07 
  baseline 10/11/2001 5.82 2.86 
    10/25/2001 6.71 2.63 
    11/1/2001 5.44 2.24 
    11/8/2001 5.20 2.66 
    11/15/2001 5.49 2.55 
    12/7/2001 7.65 2.83 
    12/20/2001 4.85 4.96 
 
 
 
 
 
 
 
 
 
Individual subject escape latency raw data of chlordiazepoxide administration 
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Average of Latency     Component   
Rat Dose Date acquisition performance 
K 3 0 x 0 12/7/2001 5.85 2.65 
    1/8/2002 6.59 1.44 
  0.03 x 1.0 12/28/2001 3.76 1.72 
    1/18/2002 3.22 1.71 
  0.03 x 3.0 12/18/2001 11.74 2.45 
    1/11/2002 4.31 2.22 
  0.1 x 1.0 12/21/2001 3.76 2.48 
    1/4/2002 4.56 1.74 
  0.1 x 3.0 12/11/2001 6.31 4.95 
    1/1/2002 8.76 2.30 
    1/15/2002 4.59 2.58 
  baseline 12/6/2001 3.89 1.71 
    12/20/2001 6.43 2.30 
    12/27/2001 6.88 2.19 
    1/3/2002 5.83 2.11 
    1/10/2002 5.91 2.14 
    1/17/2002 2.58 2.09 
K 6 0 x 0 12/7/2001 13.14 1.86 
    1/8/2002 3.64 2.13 
  0.03 x 1.0 12/28/2001 5.03 1.76 
    1/18/2002 3.04 1.82 
  0.03 x 3.0 12/18/2001 3.37 2.40 
    1/11/2002 4.85 2.46 
  0.1 x 1.0 12/21/2001 5.39 2.28 
    1/4/2002 5.45 2.69 
  0.1 x 3.0 12/11/2001 22.98 21.47 
    1/1/2002 27.34 2.99 
    1/15/2002 10.04 3.42 
  baseline 12/6/2001 5.93 2.12 
    12/20/2001 6.70 2.20 
    12/27/2001 7.69 2.58 
    1/3/2002 4.13 2.47 
    1/10/2002 3.92 2.15 
    1/17/2002 4.40 1.92 
K 8 0 x 0 12/4/2001 3.56 1.97 
    1/8/2002 5.07 1.54 
  0.03 x 1.0 12/7/2001 5.42 2.08 
    12/28/2001 6.60 1.88 
  0.03 x 3.0 12/18/2001 4.04 2.38 
    1/11/2002 4.38 2.52 
  0.1 x 1.0 12/21/2001 5.92 2.03 
    1/4/2002 14.74 2.04 
  0.1 x 3.0 12/11/2001 22.86 11.62 
 100 
    1/1/2002 8.96 2.52 
    1/15/2002 4.66 3.63 
  baseline 12/6/2001 3.61 1.96 
    12/20/2001 4.66 2.19 
    12/27/2001 5.99 2.07 
    1/3/2002 3.62 2.26 
    1/10/2002 3.79 1.69 
L 4 0 x 0 1/8/2002 7.59 2.23 
    1/29/2002 4.67 2.50 
    2/12/2002 4.11 2.24 
  0.03 x 1.0 12/28/2001 7.06 2.62 
    1/18/2002 18.01 2.25 
  0.03 x 3.0 1/11/2002 9.32 3.09 
    1/22/2002 3.55 3.05 
    2/8/2002 7.21 2.87 
  0.1 x 1.0 1/4/2002 11.95 3.40 
    2/1/2002 3.21 3.01 
    2/15/2002 6.88 2.53 
  0.1 x 3.0 1/1/2002 28.14 4.62 
    1/15/2002 5.46 4.23 
    2/5/2002 22.25 3.19 
  baseline 12/27/2001 5.80 4.33 
    1/3/2002 5.15 3.11 
    1/10/2002 4.44 2.59 
    1/17/2002 3.59 2.69 
    1/31/2002 9.58 3.47 
    2/7/2002 4.23 2.68 
    2/14/2002 4.16 2.77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Individual subject escape latency raw data of dizocilpine-chlordiazepoxide 
administration 
 101 
Appendix H 
 
 
 
Average of Latency     Component   
Rat Dose Date acquisition performance 
K 3 0 2/5/2002 4.75 2.20 
    4/9/2002 3.30 2.37 
    2/12/2202 8.97 2.36 
  0.03 1/29/2002 3.61 1.58 
    3/26/2002 3.88 3.65 
  0.1 2/1/2002 4.89 3.32 
    2/22/2002 5.64 4.08 
  0.17 2/8/2002 13.84 5.50 
    3/29/2002 6.79 1.84 
    4/2/2002 9.00 2.80 
    4/23/2002 4.78 2.75 
  0.3 2/15/2002 5.05 4.39 
    3/19/2002 10.11 2.00 
    4/12/2002 12.21 3.98 
    4/26/2002 5.11 1.88 
  1 2/19/2002 6.91 3.52 
    3/15/2002 24.57 5.24 
    4/16/2002 8.33 3.52 
    4/19/2002 18.79 9.35 
  1.7 2/26/2002 22.46 6.47 
    3/22/2002 10.69 6.90 
  baseline 1/31/2002 7.01 1.93 
    2/7/2002 7.64 1.99 
    2/14/2002 5.46 2.07 
    2/21/2002 5.70 1.70 
    3/14/2002 6.27 1.78 
    3/21/2002 6.31 1.84 
    3/28/2002 4.71 1.84 
    4/11/2002 5.96 2.11 
K 6 0 2/5/2002 6.10 3.51 
    2/12/2002 5.74 1.73 
    4/9/2002 4.45 2.58 
  0.03 1/29/2002 4.89 2.09 
    3/26/2002 4.29 2.01 
  0.1 2/1/2002 3.05 2.72 
    2/22/2002 5.24 1.65 
  0.17 2/8/2002 4.44 1.99 
    3/29/2002 2.93 1.92 
  0.3 2/15/2002 3.98 1.81 
    3/1/2002 6.76 5.50 
    3/19/2002 6.16 1.93 
    4/12/2002 8.58 2.19 
  1 2/19/2002 13.96 3.69 
 102 
    3/15/2002 15.67 4.19 
    4/5/2002 7.79 2.90 
    4/19/2002 25.31 2.40 
    3/22/2002 4.54 2.49 
    4/2/2002 3.51 2.35 
    4/16/2002 34.23 14.69 
  baseline 1/31/2002 4.26 2.50 
    2/7/2002 8.93 1.72 
    2/14/2002 4.63 2.00 
    2/21/2002 5.11 2.07 
    2/28/2002 3.50 2.51 
    3/14/2002 3.88 2.75 
    3/21/2002 3.93 3.05 
    3/28/2002 5.26 1.89 
    4/4/2002 7.75 2.51 
    4/11/2002 6.10 2.38 
    4/18/2002 3.83 2.35 
K 8 0 2/2/2002 7.36 1.69 
    2/12/2002 4.57 1.69 
    4/9/2002 4.95 1.99 
  0.03 1/29/2002 4.73 1.77 
    3/26/2002 3.27 1.88 
  0.1 2/1/2002 3.09 6.61 
    2/22/2002 6.07 2.43 
    4/19/2002 5.84 1.82 
    4/26/2002 4.67 2.45 
  0.17 2/8/2002 40.82  
    3/29/2002 3.52 2.17 
    4/2/2002 4.70 2.85 
    4/23/2002 4.84 2.35 
  0.3 2/15/2002 14.51  
    3/19/2002 6.45 2.16 
    4/12/2002 4.26 2.79 
  1 2/19/2002 3.08  
    3/15/2002 8.86 5.72 
    4/5/2002 9.77 3.85 
    4/16/2002 6.76 2.28 
    4/30/2002 5.88 2.31 
  1.7 3/22/2002 8.12 6.25 
    5/3/2002 15.97 2.68 
    5/7/2002 4.14 2.55 
  baseline 1/31/2002 6.94 2.01 
    2/7/2002 5.36 1.92 
    2/14/2002 3.30 2.45 
    2/21/2002 6.65 1.88 
    3/14/2002 3.20 2.07 
    3/21/2002 4.68 2.00 
    3/28/2002 3.12 2.09 
    4/4/2002 6.42 1.80 
    4/11/2002 5.24 2.10 
 103 
    4/18/2002 9.11 1.98 
  1 3/15/2002 16.55 14.07 
    4/5/2002 10.30 4.80 
    4/30/2002 19.30 8.46 
  1.7 3/22/2002 16.82 8.64 
    4/16/2002 48.26 34.45 
  baseline 2/28/2002 4.02 2.76 
    3/14/2002 4.27 2.75 
    3/21/2002 4.74 2.46 
    3/28/2002 7.50 2.41 
    4/4/2002 6.08 2.27 
    4/18/2002 4.41 2.96 
    4/25/2002 5.08 2.67 
    5/2/2002 6.27 2.81 
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Appendix I 
 
 
 
Average of Latency     Component   
Rat Dose Date acquisition performance 
K 3 0 x 0 5/7/2002 2.32 8.32 
    5/28/2002 4.74 2.22 
  0.3 x 3.0 5/21/2002 21.58 2.82 
    6/11/2002 20.80 2.43 
  0.3 x 5.6 5/17/2002 53.44 3.58 
    5/31/2002 12.97 3.02 
  1.0 x 3.0 5/14/2002 9.16 4.96 
    6/4/2002 41.79 5.44 
  1.0 x 5.6 5/25/2002 8.64 4.98 
    6/8/2002 19.35 4.83 
  baseline 5/16/2002 4.89 1.98 
    5/23/2002 6.49 1.90 
    5/30/2002 4.08 1.60 
    6/7/2002 5.00 1.56 
K 6 0 x 0 4/26/2002 3.99 1.86 
    5/28/2002 4.83 1.87 
  0.3 x 3.0 5/3/2002 7.06 2.83 
    5/21/2002 8.68 2.20 
  0.3 x 5.6 5/17/2002 19.03 2.82 
    5/31/2002 9.90 2.23 
  1.0 x 3.0 5/14/2002 36.14 3.88 
    6/4/2002 33.49 8.98 
  1.0 x 5.6 4/30/2002 9.38 9.14 
    5/24/2002 6.43 2.81 
    6/8/2002 18.41 8.54 
  baseline 4/25/2002 3.68 2.11 
    5/2/2002 5.74 2.24 
    5/16/2002 4.03 2.26 
    5/23/2002 6.80 1.98 
    6/6/2002 4.14 1.70 
K 8 0 x 0 5/28/2002 3.53 1.77 
  0.3 x 3.0 5/21/2002 43.84 2.80 
    6/11/2002 14.85 2.25 
    5/31/2002 5.35 2.67 
  1.0 x 3.0 5/14/2002 4.38 2.49 
    6/4/2002 21.34 2.88 
  1.0 x 5.6 5/24/2002 6.03 3.35 
    6/8/2002 7.22 5.05 
    6/14/2002 6.46 4.63 
  baseline 5/16/2002 4.10 2.19 
    5/23/2002 2.66 1.71 
    5/30/2002 2.89 1.50 
    6/7/2002 2.74 1.43 
 105 
    6/13/2002 4.85 2.00 
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